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ABSTRACT OF DISSERTATION

Plant-Based Multicomponent Vaccines against Enteric Diseases
by
Jie Yu

Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, March 2001
Dr. William H.R. Langridge, Chairperson
To generate a plant-based multicomponent oral vaccine against cholera,
rotavirus and enterotoxigenic E.coli (ETEC), we have constructed transgenic potato
plants that synthesize the cholera toxin B and A2 subunits, the rotavirus enterotoxin
NSP4 22 amino acid epitope and the ETEC fimbrial antigen CFA/L To use cholera
toxin as a carrier molecule for delivery of multiple antigens to the gut-associated
lymphoid tissues, the rotavirus NSP4 epitope was linked to the cholera toxin B
subunit (CTB) and the ETEC fimbrial antigen CFA/I was linked to the cholera toxin
A2 subunit. Cholera toxin-antigen fusion proteins were detected in transformed tuber
tissues by immunoblot assay and quantitated by enzyme linked immunosorbent assay
(ELISA). The CTB-NSP4 protein expression level was found to be approximately
0.01% of total soluble plant protein (TSP) and the CFA/I-CTA2 protein expression
level was about 0.002% of TSP. Assembly of the CFA/I-CTA2 subunit into the CTBNSP4 pentamer was detected by immunoblot and Gmi ELISA assays. The CFA/ICTA2-CTB-NSP4 hetero-hexamer fusion protein complex retained its binding
affinity for Gmi ganglioside enterocyte membrane receptors. Serum and intestinal

xi

antibodies against NSP4, CFA/I and CTB were detected in orally immunized mice.
Analysis of IL-2, IL-4 and IFNy cytokine levels in splenocytes isolated from
immunized mice indicated the presence of a strong Thl immune response to the plant
synthesized antigens. Fluorescent antibody based flow cytometry analysis of
immunized mouse spleen cells showed an increase in CD4+ T -helper cell
populations. Following rotavirus challenge, passively immunized mouse pups showed
a 50% reduction in diarrhea symptoms.
To generate a plant-based subunit vaccine against rotavirus, we have expressed the
gene encoding rotavirus capsid protein VP6 in transgenic potato plants. The plant
produced VP6 protein has a molecular mass similar to VP6 purified from virus and
partially formed VP6 trimers. Mice fed transformed potato tubers containing VP6
generated serum and intestinal antibodies against VP6. The results of these
experiments indicate that food plants can serve as safe and inexpensive vaccine
production and distribution systems for simultaneous immunization against several
diseases.
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CHAPTER ONE
INTRODUCTION
1.

General
The vaccine concept was first introduced by the English physician Edward Tenner in

the late 18th century when he inoculated an 8-year-old boy, James Phipps with cowpox
virus isolated from a milkmaid. This procedure called vaccination helped the patient
develop resistance to smallpox. After more than a hundred years development,
vaccination has become one of the most cost -effective medical intervention methods
available for control and eradication of disease epidemics worldwide. However,
implementation of a global vaccination program in developing nations has not been
possible due to a combination of poor economic conditions and political unrest resulting
in an inadequate health care infrastructure, and a prohibitive cost of essential vaccines.
To rectify this situation changes are required in the way vaccines are produced,
distributed and administered to make them more effective, less expensive, easier to
administer and more widely available. In 1990, the World Health Organization (WHO)
launched the Children’s Vaccine Initiative establishing goals for developing vaccines that
are safe, inexpensive, easily (orally) administered and widely accessible (Mitchell et al.,
1993). Establishment of these goals ultimately led to the idea of producing oral vaccines
in transgenic food plants (Mason et al., 1992).
In this dissertation we propose the construction of a multi-component oral vaccine in
potato plants for prevention against three infectious enteric diseases: cholera, rotavirus
and enterotoxigenic Escherichia coli (ETEC). In our vaccine design, the non-toxic
cholera toxin B subunit was employed as a carrier molecule for targeting plant derived
1

antigens to the intestinal mucosal immune system. Genes encoding antigens or antigen
epitopes from rotavirus and ETEC pathogens were fused to the cholera toxin B subunit
and the recombinant proteins were synthesized in transformed potato leaf and tuber
tissues. The protective efficacy of this multi-component food plant based oral vaccine
was tested in mice. The experimental results generated by this project will help us
determine the advantages and circumvent the difficulties in establishing food plants as
vehicles for the production and delivery of multi-component vaccines for protection
against infectious enteric diseases. The results of the proposed experimentation will
permit us to improve the first generation plant vaccines to achieve greater targeting
ability and higher expression levels for possible use in human vaccine clinical trials.
2.

Transgenic Plants as Vaccine Production and Delivery Systems
Traditional methods of plant breeding have been practiced for hundreds of years with

great success in improving plant characteristics and agricultural properties, such as
improved protein content, resistance to insect and fungal attack and resistance to virus
and bacterial disease. However the classical plant breeding approach is slow and
imprecise due to the transfer of all the traits of the donor organism, which can alter the
expression of the desired gene products. However in the past decade, the advent of
modem molecular biology methods, especially recombinant DNA techniques has made a
huge impact on plant biotechnology (Schell, 1987). The relatively short time required to
identify and clone specific genes encoding desirable traits has made plant systems
particularly valuable for production of recombinant molecules (Amtzen et ah, 1995,
1997; Hugh et ah, 1995). Genetic engineering technology has also been applied to the
production of proteins of therapeutic value, especially pharmaceuticals and vaccines
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(Figure 1.). The first reported vaccine candidate expressed in transgenic plants was the
cell surface adhesin protein (spa A) from streptococcus mutans, a major bacterial cause
of tooth decay (Curtiss et ah, 1990). The spa A gene was introduced into tobacco by
agrobacterium- mediated transformation methods. The protein was expressed at levels of
up to 0.02% of total leaf protein. Oral immunization with this plant-synthesized vaccine
stimulated the production of protective secretary IgA in saliva. The 185kD size of spa A
protein demonstrated the ability of the plant genome to accommodate large foreign gene
inserts.
A great advantage of plant genetic engineering is that whole plants can be regenerated
from single transformed cells. When a plant is wounded, a patch of fast growing cells
called callus tissue grows over the surface of the wound. If a piece of this young callus
tissue is removed and placed in a culture medium containing the appropriate nutrients and
plant growth hormones, the cells will continue to grow and differentiate into shoots and
roots and ultimately a whole flowering plant will be produced. Thus transgenic plants can
be conveniently grown to produce stable breeding lines which can be propagated by
conventional horticultural techniques and stored and distributed as seeds or vegetative
proteins (tubers). Unlike bacterial or animal cells, plant cultivation is straightforward,
does not require special media or equipment. Due to their photo synthetic nature, plants
require only water, CO2, soil and sunlight for growth and development. An obvious
benefit of plants is the potential for scaled-up production (Tsafrir et ah, 1998), in which
large amounts of recombinant protein can be produced at a minimal cost. Agracetus, a

3

HOW TO MAKE AN EDIBLE VACCINE
One way of generating edible vaccines relies on the
bacterium Agrobacterium tumefaciens to deliver into
plant cells the genetic blueprints for viral or bacterial
BACTERIAL CELL
ANTIGEN GENE-

"antigens"—proteins that elicit a targeted immune
response in the recipient.The diagram illustrates the
production of vaccine potatoes.

PLANT CELL
DNA

PLASMID
ANTIBIOTICRESISTANCE
GENE

BACTERIAL
SUSPENSION

GENETRANSFER
DEAD CELL

CALLUS
VACCINE
POTATOES

4^

7 Cut leaf.

2 Expose leaf to bacteria carrying an antigen
gene and an antibioticresistance gene. Allow
bacteria to deliver the
genes into leaf cells.

3 Expose leaf to an antibiotic to kill cells that lack
the new genes. Wait for
surviving (gene-altered)
cells to multiply and form
a clump (callus).

4 Allow callus to sprout
shoots and roots.
5 Put in soil. Within three
months,the plantlets will
grow into plants bearing
antigen-laden vaccine potatoes.

Fig. 1. Production of oral vaccines in transgenic plants, (cited from Langridge, Scientific American 2000.)

plant biotech company, has developed a strain of com that can produce 1.5 kg of
pharmaceutical quality antibodies per acre. A cost-effective analysis carried out by the
Scripps Research Institute showed that the antibodies could be produced at approximately
one US dollar per gram (Ma et al., 1999).
To develop a recombinant subunit vaccine, the immunogenicity of the antigen
depends on correct protein folding, structure and post-translational modifications. The
eukaryotic system of plants provides significant advantages over bacterial or viral
expression systems with respect to these issues. With regard to protein folding and
stmcture, small peptides, polypeptides and even fully assembled and functional complex
proteins can be expressed in plants. For larger protein molecules, assembly and protein
folding are associated with the presence of ER-resident chaperones that are homologous
with those involved in protein assembly in mammalian cells. Targeting recombinant
proteins for secretion through the ER and Golgi apparatus can be achieved using either
native or plant leader sequences (Maarten et al., 1992; Heijine, 1985; Munro et ah, 1987).
A typical example is the co-expression of antibody heavy and light chains to form a fulllength antibody, functionally identical to its mammalian counterpart (Hiatt et al., 1989).
Expression of the rabies vims glycoprotein in trangenic tomatoes demonstrated the ability
of plant cells to carry out post-translational glycosylation essential for the biological
function of proteins of animal origin (McGarvey et al., 1995). The plant glycosylation
pattern differs somewhat from mammals in the composition of the complex glycans. The
complex glycans in plant proteins tend to be smaller than mammalian complex glycans
and differ in the terminal sugar residues. But for recombinant proteins expressed so far,
this difference has not led to any detectable loss of stmcture or function.

5

Additional advantages of the plant production system include biological safety and
ease of purification. Plant viruses do not infect humans. Plant produced vaccines
eliminate the contamination of animal viruses. If tissue specific promoters are used, the
vaccine antigens can be exclusively expressed in storage organs such as seeds, fruits or
tubers (Arakawa et al., 1997; McGarvey et ah, 1995; Wenzler et ah, 1989). Extraction
and purification from these tissues is relatively simple. The idea of an edible plant
vaccine is also very tempting from a simplicity perspective. Vaccines produced in
transgenic plants can be harvested by conventional machinery and administrated simply
by eating the fruit or tubers that contain the appropriate amount of vaccine antigen
required for immunization (Amtzen, 1997). To date there are more than 30 antigens from
infectious pathogens and auto antigens from auto-immune diseases that have been
produced in a variety of plants (Ma et ah, 1999). The history and strategies for
development of plant-based vaccines will be discussed in more detail in chapter three.
3. Mucosal Immune System
The mammalian mucosal immune system is an integrated network of antigen
presenting tissues, lymphoid, cells and effector molecules, substantially different from
the peripheral immune system, where lymphoid cells and effector molecules are confined
to individual lymph nodes and spleen tissues where intercommunication occurs only by
cell trafficking through the lymphatic and blood circulation (Kiyono et ah, 1996).
Another major difference is that induction of the peripheral immune response does not
result in significant mucosal immunity. In contrast, induction of mucosal immune
response can result in protective immunity in both the peripheral compartment (blood and
lymph) and at mucosal sites such as the lumen of the intestine (Freytag et al., 1999).

6

When we consider that most infectious agents come in contact with the host at mucosal
surfaces, the use of oral vaccines becomes the most attractive approach for immunization.
The induction of mucosal immune responses by oral vaccines may not only protect the
host from morbidity and mortality due to infection, but possibly prevent infection
altogether (Brandtzaeg et al, 1995).
a. The Anatomy of Mucosal Immune System
The respiratory and digestive mucosal surfaces are enormous, approximately 3004,000 m2 in humans. The mucosal immune system comprises over 80% of all
immunoglobulin producing cells in human body (Kiyono et al., 1996). The mucosal
inductive site of the gastrointestinal tract is the Peyer’s patch which is enriched for
macrophages, B and T cells and contains the germinal center for B-cell differentiation.
The surface of the Peyer’s patch is covered by a unique epithelium called the follicle
associated epithelium (FAE). The intestinal lumen side of the FAE is rich in specialized
antigen sampling cells known as M cells, which have thin cytoplasmic extensions
surrounding the lymphoid cells (Figure 2.). The M cells are more permeable to the gut
contents than other epithelial cells in the villus epithelium (Levine et al., 1983; Neutra et
al., 1994). Accumulated experimental results support the concept that antigen uptake by
M cells does not result in degradation of the antigen, but rather results in delivery of
intact antigens to the underlying lymphoid tissues (Neutra et al., 1987; Giannasca et al.,
1994). The production of class IIMHC molecules by M cells suggest that they may also
play a significant role in presenting antigens to local T cells (Farstad et al., 1994; Allan
et al., 1993). Once antigens have traversed the M cells, other antigen presenting cells(macrophages and dendritic cells) within the Peyer’s patches take them up and present

7

A1 subunit
22 kDa

A2 subunit
5 kDa

B subunit pentamer
11.6 kDa / monomer

oo

Enterocyte
Membrane

Ganglioside

Central
pore
Fig. 3. Composite model for cholera holotoxin bound to the saccharide moieties of five receptor molecules.
(Modified from Mucosal Vaccines 1996, Academic Press.)

them to adjacent regulatory T helper cells (Langhoff and Steinman, 1989), which produce
specific cytokines (IL-2, IL-12, IFN-y) stimulating B cell division and differentiation.
The stimulated B cells migrate into the lymphatic and blood circulation and subsequently
localize in mucosal effector regions through interaction with specific cellular receptors on
endothelial venules. Within the mucosal tissues, e.g., the lamina propria of the gut and
the respiratory tract, the sensitized B cells mature into plasma cells and secrete mucosal
IgA antibodies into the lumen of the intestine.
b. Secretory Immunoglobulin A
Secretory IgA (slgA) is a polymeric immunoglobulin, comprising two or more IgA
antibody monomers bound together by a polypeptide referred to as the J chain.
Approximately 40mg/Kg body weight of IgA is made daily in mucosal tissues. The daily
production of IgA exceeds production of immunoglobulins of all other antibody isotypes
combined (Mestecky and McGhee, 1987). Protective mucosal immunity is mediated
mainly through the local production of slgA. Secretory IgA has several important
biological functions (Childers et ah, 1989). Secretory IgA is polymeric, thus it has greater
binding capacity than monomeric IgA and is more effective at virus neutralization. The
ability of slgA to neutralize influenza virus was demonstrated by Taylor and Dimmock
(Taylor et ah, 1985). Binding of influenza virus to a cell monolayer was prevented by
slgA by interfering with virus attachment or internalization, Monomeric IgA or IgG was
unable to prevent virus binding to the cells. Intravenously administered polymeric IgA
was shown to be transported across the nasal epithelium of mice and provided local
protection against influenza virus challenge (Renegar et ah, 1991). The multivalence of
slgA also allows the antibodies to more efficiently agglutinate bacteria. A monoclonal
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IgA directed against a single surface epitope of Vibrio cholerae protected neonatal mice
against a normally lethal dose of vibrios (Winner et al.,1989). The antibacterial activity of
slgA is enhanced by its ability to increase the activity of innate antibacterial factors, such
as lactoferrin, peroxidases, and lysozyme (Rogers et al, 1978; Tenuovo et al., 1982;
Adinolfi et al., 1966). Secretory IgA has also been shown to exert antibacterial activity
through an indirect mechanism involving antibody-dependent cell -mediated cytotoxicity
(ADCC). For example, T cells bound with IgA have been shown to effectively kill
Salmonella and Shigella (Tagliabue et al., 1989). Immune exclusion is another immune
mechanism mediated mainly through slgA. During immune exclusion slgA binds to
microorganisms, toxins and antigens in the lumen or mucus, preventing their absorption
into the blood circulation (Walker et al., 1977). The immune complexes formed with
slgA are more readily cleared from the circulation than antigens alone (Walker and
Bloch, 1976). The inhibition of local inflammatory responses by slgA also prevents the
enhanced permeability of the mucosa to bystander antigens.
Cell-mediated immunity of the mucosal immune system is much less studied than
antibody responses. The distribution patterns and unusual phenotypes of T lymphocytes
suggest the role of regulation of intestinal immunity. Intraepithelial T lymphocytes (IEL)
are abundant in the small intestine and are predominantly CD8+ cells, while the lamina
propria lymphocytes (LPL) are predominantly CD4+ cells, the IEL may be functional
suppressor cells involved in the mediation of oral tolerance. The LPL cells appear to
induce isotype switching to IgA plasma cells (Elson et al., 1983).
Many factors affect the mucosal immune response, these include the dose of antigen,
the immunization protocol, the type of adjuvant and the nature of the antigen. It has been
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shown in many studies that large doses of antigen are required to induce a slgA response
following oral immunization (Michalek et ah, 1977). However by using adjuvants and
specific targeting strategies, the amount of antigen used can be greatly reduced. The
nature of the antigen also plays an important role in mucosal immunity. Secretory IgA is
induced most effectively by living rather than killed antigens (Bergmann et al., 1988).
Particulate antigens are more immunogenic than soluble antigens (Cox et al., 1984).
Intracellular pathogens tend to induce a Thl cell response, while extracellular pathogens
tend to induce Th2 cell responses. The induction of mucosal immunity following oral
immunization has been shown to depend upon a number of variables. Consequently,
several vaccine delivery strategies may be combined to develop more effective oral
vaccines.
4. Immune Modulation by Cholera Toxin
a. Structure and Basis of Cholera Toxin Activity
Cholera toxin (CT) isolated from the gram negative diarrhea causing bacteria Vibrio
cholerae has been shown to enhance the immunogenicity of mucosal immunogens when
mixed with or conjugated to the antigens and given orally (Jaskson et al., 1993; Lycke et
al., 1986; Mckenzie et al., 1984). Thus CT and its nontoxic B subunit have generated
significant interest as potential adjuvants for oral vaccines. The molecular structure of CT
has been studied extensively (Zhang et al., 1995; De Wolf et al., 1981). Cholera toxin is a
hetero-hexameric protein in which a single A subunit is associated with a ring-like B
pentamer formed by the association of five identical B monomers (Figure 3.). The A
subunit is readily cleaved by exogenous proteases to form Al and A2 peptide fragments,
linked via a single disulphide bond (Hoi et al., 1995). By a still unclear mechanism the
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A1 subunit enters the cell cytosol and catalyses ADP-ribosylation of a Gs protein, which
continuously activates adenylate cyclase leading to an elevation in cyclic AMP (cAMP)
levels in the cell (Stavric et ah, 1978). Raised cAMP levels cause protein kinase A to
phosphorylate membrane porin proteins and open the transmembrane Cf channel.
Chloride ion efflux results in the concomitant osmotic movement of water into the gut
lumen and characteristic profuse watery diarrhea. The A2 fragment is an adaptor peptide
whose major functions are to interact with the B subunit and position the A1 subunit
above the B subunit pentamer (Zhang et ah, 1995). The C-terminus of the A2 fragment
contains a KDEL sequence motif that is associated with retrieval of proteins from the
trans-Golgi network to the endoplasmic reticulum (ER). This KDEL sequence is
important for delivery of the A1 peptide fragment to the correct cellular compartment,
which may have an important role in modulating the imunological effects of the toxin
(Hirst and Holmgren, 1987). The B subunit monomers interact with each other through
hydrogen bonding of two three-stranded anti-parallel p sheets. This feature, together with
the high number of salt bridges between adjacent B monomers makes the CTB pentamer
one of the most stable non-covalently associated protein complexes known (Williams et
al., 1999). The CTB pentamers are stable in Img/ml trypsin or proteinase K, and at acid
pH (pH2.0). The CTB pentamers bind to the Gmi ganglioside ubiquitously presented on
mammalian cell surfaces, including the cell surface of intestinal epithelial cells (Merrit et
al., 1994).
b. Cholera Toxin as A Mucosal Adjuvant
The adjuvant activity of CT for orally delivered antigens was first reported by Elson
and Ealding in 1984. Cholera toxin was fed to mice either alone or with the unrelated

12
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Fig. 2. The anatomy of mucosal immune system, (cited from Mucosal Vaccines 1996, Academic Press.) The follicleassociated epithelium in a rabbit Peyer’s patch contains many M cells (M), identified by their short, sparse microvilli
and thin apical cytoplasm, interspersed with enterocytes, identified by their microvillous brush borders (bb). The
intraepithelial pockets formed by contiguous M cells are very large and contain B and T lymphocytes and
macrophages. The basement membrane (bm) is interrupted to accommodate cellular traffic between the intraepithelial
pockets and the subepithelial tissue.

protein antigen, keyhole limpet hemocyanin (KLH). When both proteins were fed
together, CT abrogated tolerance to KLH. At the same time, CT also induced an intestinal
slgA response to KLH, which did not occur when KLH was fed alone (Elson and
Balding, 1984). Since these pioneering experiments a variety of antigens have been used
to test the adjuvant activity of CT. Cholera toxin has shown adjuvant activity with a
remarkably broad array of antigen types, including protein antigens, lipid antigens,
carbohydrate antigens, as well as whole viruses, bacteria, and a protozoan. In order for
CT to have adjuvant activity it must be administered simultaneously with the antigen by
the same immunization route (Lycke and Holmgren, 1986). This suggests that CT acts on
mucosal lymphoid tissues in contact with the antigens. The dose of CT required to
demonstrate the adjuvant effect for most protein antigens in mice ranges between 1 to
lOug/dose (Lycke and Holmgren, 1986; Kusnecov et ah, 1992). Equivalent mucosal
adjuvanticity of the holotoxin in mice can be achieved by using the CTB subunit
containing trace amounts (0.1-5%) of CT (Wilson et ah, 1990; Lee and Chen, 1994). This
method is very attractive as it reduces the A subunit toxicity enough to allow use in
humans, particularly with the intranasal route of administration. Long-term mucosal and
systemic memory B and T-cell responses to co-administered antigens are induced by CT
(Jackson et al., 1993). The response is CD4+ T-cell dependent and requires antigen
presentation via class II MHC molecules. T-cell responses to CT are predominantly of the
Th2 cell type (Williams et al., 1999; Xu-Amano et al., 1993). This finding is supported
by the observation that the serum antibody response is dominated by IgGl. Balanced Thl
and Th2 cytokine responses and a predominant Thl response stimulated by co
administered CT were also reported (Rappuoli et al., 1999). It is important to note that the
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adjuvanticity of CT is influenced by genetic background as well as the nature of the co
administered antigen (Hiroshi et ah, 1996).
c. Role of CT Subunits in Mucosal Adjuvanticity.
The involvement of the A and B subunits in mediating CT adjuvant activity has been a
source of ongoing controversy. Horseradish peroxidase (HRP) chemically conjugated to
CTB was found to elicit higher antibody levels in the gut and serum than feeding HRP
alone, or an unconjugated mixture of HRP and CTB (McKenzie and Halsey, 1984). This
study demonstrated that CTB has intrinsic adjuvant activity. However, the use of CTB
conjugates has been reported to be effective in some cases, but not in others. The poor
response in other cases may be due to the coupling procedure, which can significantly
affect the immunogenicity of protein conjugates. More recently recombinant DNA
technology has made it possible to genetically fuse peptides to CTB. Chimeric CTB
fusions demonstrated adjuvant activity of CTB, but the activity was not as strong as what
was found with the holotoxin in the intestine (Holmgren et al., 1993; Dertzbaugh et al.,
1989). The size of the peptide that can be fused to CTB is restricted to about 20 amino
acid residues. Larger peptides tend to disrupt the formation of CTB pentamers, abolish
the GM1 ganglioside binding activity and eventually impair the adjuvant effect. An
alternative solution to this problem was to replace the toxic Al subunit of CT with
relatively large size antigens. The resulting fusion protein containing the A2 subunit
reassembled with the CTB pentamer to form a holotoxin-like structure. A CTB fusion
protein containing a Streptococcal adhesin molecule (42kD) constructed in this way
induced strong slgA and serum IgG responses in orally immunized mice (Hajishengallis
et al., 1995). In another report, mixtures of KLH and CTB were unable to stimulate
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immunity to KLH unless a very small amount of holotoxin (<50ng) was added (Lycke
and Holmgren, 1986). This leads to the conclusion that adjuvant activity was dependent
on ADP-ribosylation by the A subunit. To settle the disparity between studies of the role
of the A and B subunits in the immunogenicity and adjuvanticity of CT, mutants that
lacked enzymatic and binding ability of both A and B subunit were generated by sitedirected mutagenesis. Mice were fed tetanus toxoid (TT) with different combinations of
A and B subunits to compare with wild-type CT (Elson et al., 1995). Mice receiving wild
type CT had strong responses to both CT and TT. Mice receiving the A mutant or CTB
alone had moderate and weak anti-CT responses, but no TT response. Mice given the B
mutant or the double A and B mutant had no response to either CT or TT. These results
show clearly that both a functional A and B subunit are required for optimal
immunogenicity and adjuvanticity of CT in the intestine.
d. Cellular Gargets of CT and CTB Adjuvant Activity
Cholera toxin and the CTB subunit do not alter antigen uptake or processing by
antigen-presenting cells (APC) in vitro, nor do they affect macrophage class II MHC
expression. However, they do enhance antigen presentation of APC in an indirect way, by
increasing the expression of costimulatory cell surface molecules (B7) and costimulatory
cytokines (IL-1 and IL-6) (Lycke et al, 1989). Increased B7 and cytokine synthesis result
in increased CD4+ T cell priming in mucosal tissues in vivo. Primed CD4+ T cells
produce cytokines such as IL-4 (Th2 type) that enhance antibody isotype and subtype
switching to IgA and IgGl respectively (Homquist et al., 1993). Both CT and CTB can
inhibit lymphocyte function in the epithelial layer, particularly CD8+ T cells, which may
produce suppressive cytokines (Williams et al., 1999). This inhibition effect abrogates
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oral tolerance to co-administered antigens. Cholera toxin does not have direct effects on
B cell isotype differentiation in vitro. Cholera toxin enhances the effect of both IL-4 and
IL-5 on purified B cells (Wilson et ah, 1990; Clarke et ah, 1991). In the presence of CT,
IL-4 enhanced IgGl producing B cells three to fourfold, and IL-5 had a similar effect on
IgA producing B cells. The mechanisms by which a given antigen triggers a Thl or Th2
dominated response are at present unclear. Thus, it is important to know what effects CT
and CTB have as mucosal adjuvants on Thl vs Th2 cell responses (Mocci et ah, 1997).
5. Infectious Enteric Diseases
Diarrhea is the most prevalent infectious disease in developing countries and ranks
second only to respiratory disease in developed countries (Kumate and Isibasi, 1986).
The majority of diarrheal illness and deaths occur in children less than 5 years of age.
Cholera , enterotoxigenic Escherichia coli (ETEC), rotavirus and Norwalk virus are the
four leading causes of diarrhea diseases worldwide.
a. Cholera
Cholera is an acute secretory diarrheal disease. There are approximately 500,000 to 1
million clinical cases of cholera worldwide annually ( Waldor et ah, 1996). In endemic
areas where quick medical treatment (rehydration therapy) is available, mortality from
cholera is usually low approximately 1-3%, but in epidemic situations mortality can
exceed 50%. In the recent 1994 cholera epidemic in Rwandian refugee camps, an
estimated 50,000 cholera fatalities occurred (Bern and Glass, 1994). Until the present
there have been seven recorded cholera pandemics. The classical biotype of V.cholerae
serogroup 01 is responsible for the first six cholera pandemics. The seventh pandemic of
cholera was caused by the El Tor biotype of V.cholerae 01 which emerged in Indonesia
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in 1961and arrived in Peru in 1991 (Kiyono et al., 1996). Since then the El Tor strain has
spread throughout Latin America and has given rise to more than a million cases. In 1992
a new serotype 0139 V.cholerae arose in India, and caused a major cholera epidemic in
south Asia. Genetic studies indicated that V.cholerae 0139 probably arose from the strain
V.cholerae 01 El Tor, by replacement of a part of the O antigen gene cluster with a non01 strain (Holmgren et al., 1996). Although the 0139 strain is currently restricted to
Asia, there is a great risk that it may follow the tracks of V.cholerae 01, reaching Africa
and Latin America.
Attempts to make parenteral cholera vaccines began soon after the discovery of
V.cholerae as the causitive agent of cholera. Field trials revealed a short-lived protective
efficacy of the parenteral killed vaccines, usually in the 30-80% protection range in the
first 6 months falling to approximately 30% thereafter (Kaper et al., 1984; Clemems et
al., 1986). When pathogenesis studies revealed that V.cholerae strains are strictly
mucosal pathogens, surviving and multiplying on the surface of the epithelium of the
small intestine without crossing the epithelial barrier. An oral cholera vaccine composed
of killed whole-bacterial cells and nontoxic B subunit (BS-WC) was developed by
Svennerholm, Holmgren, and colleagues and tested in Bangladesh. This vaccine provided
up to 85% protection against cholera infection in all age groups for the first six months,
decreasing to about 51% protection after 36 months (Holmgren et al., 1996). Killed
whole-cell (WC) or BS-WC oral cholera vaccines were evaluated in clinical trials in the
U.S. and provided 56% and 64% protection against cholera infection respectively
(Waldor et al., 1996). Further, BS-WC vaccine gave protection against both cholera and
ETEC for the first 3 months of the trial, indicating immunological cross-protection
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between the two bacterial pathogens. Recombinant live-attenuated oral cholera vaccines
containing a deletion in the toxic A subunit or both A and B subunits were also tested in
clinical trials. This vaccine had a protective efficacy of 90%. Safety is a major concern
when using recombinant live attenuated vaccines due to the possibility of reactogenicity
in vaccinees and reversion of the recombinant strain to the virulent wild-type. Ultimately
prevention and eventual eradication of cholera depends on pathogen free water sources
and an effective sanitation system. However, the poor economic conditions in developing
nations make this goal virtually impossible to achieve. Thus, a cost-effective oral vaccine
which can provide repeated protection or long lasting protection has become the most
urgent need.
b. Enterotoxigenic Escherichia Coli
Enterotoxigenic E. coli is one of the most common causes of diarrhea and
mortality in children in developing countries and continues to be a common cause of
traveler’s diarrhea in adults. About one third of all ETEC infections are symptomatic in
children, but this is enough to result in at least 650 million episodes of diarrhea and about
800,000 deaths annually in children below the age of 5 years (Black, 1990). Without
comparison, ETEC is the most common cause of traveler’s diarrhea. It has been
estimated that at least 50% of persons travelling to developing countries experience
diarrheal disease, and ETEC is isolated in one third to one half of these episodes.
Enterotoxigenic E. coli infects humans by colonization of the small intestine followed by
secreting one or more enterotoxins which induce electrolyte and water secretion from the
intestine, resulting in diarrhea (Levine et al., 1983). The enterotoxins produced by ETEC
include a heat labile enterotoxin (LT) and a heat stable enterotoxin (ST) (Lopez et al.,
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1990). The LT toxin is structurally, functionally and immunologically similar to CT.
Antibodies against CTB induce significant cross protection against diarrhea caused by LT
producing E.coli (Svennerholm et ah, 1986). In ETEC infection, colonization of the
intestine is promoted by distinct attachment factors (Michaud et al., 1990; Buhler et al.,
1991). There are three major types of colonization factor antigens (CFAs), referred to as
CFA/I, CFA/II or CFA/IV. Colonization factor CFA/I consists of approximately 100
identical 15 kDa subunits. Colonization factor CFA/II consists of three different
subcomponents, CS1, CS2 and CS3. Colonization factor CFA/IV is composed of CS4,
CSS and CS6 subunits. Anti-CFA antibodies have been found to cooperate synergistically
with anti-LT antibodies in protecting against ETEC infection (Svennerholm et al., 1989).
Based on the cross protection between anti-CTB and anti-LTB antibodies, an oral ETEC
vaccine was designed. This vaccine contains recombinant CTB and five different E.coli
strains expressing CFA/I and different fimbrial subcomponents of CFA/II and CFA/IV.
This vaccine was found to have a potential protective efficacy of at least 70-80% (Ahren
et al., 1993).
c. Rotavirus
Rotavirus is a major cause of diarrhea in young children and animals worldwide.
Virtually all children have been infected with rotavirus by the time they are 5 years old
(Bishop et al., 1983). The health burden of rotavirus disease is staggering. In developing
countries, 20 to 40% of hospitalizations and 870,000 deaths for childhood diarrhea are
associated with rotavirus infection each year (Bajolet et al., 1998). In the U.S. about 3.5
million cases occur each year, although the mortality rate is relatively low (75 to 125
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deaths each year), the direct and indirect cost of rotavirus infection exceeds one billion
dollars.
Rotavirus was first identified in 1958. It is a member of the Reoviridae family.
Rotavirus contains 11 segments of dsRNA, each coding for one protein. There are six
structural proteins in the virus particle and five nonstructural proteins expressed in
infected cells (Figure 4.). Morphologically, rotavirus particles consist of three concentric
protein capsid layers. The outer capsid layer is made of VP4 (the spike protein) and VP7
(a glycoprotein). Both capsid proteins induce neutralizing antibodies (Estes, 1996).
Capsid protein VP6 is the subgroup antigen, and makes up the intermediate protein shell
(Hsu et ah, 1997). Capsid protein VP2 forms the inner core of the virus particle. The 11
segments of genomic dsRNA reside inside the VP2 capsid layer. Serotype specificity is
defined by a binary classification system referred to as the P (VP4) serotype and the G
(VP7) serotype (Mackow et ah, 1989). Currently 14 G and 10 P rotavirus serotypes are
known. In humans, 9 G and 8 P serotypes have been identified, but the majority of
infections are due to rotaviruses of G1-G4 and P4 or P8 serotypes. Overall, the G1
serotype occurs most frequently, but multiple serotypes or strains of rotavirus often
circulate in a given community at the same time or within the same year. Antibodies to
VP4 and VP7 are each independently associated with protection against rotavirus
challenge in various animal models (Ward et ah, 1990). Protection against rotavirus is
generally serotype specific. The immune response and protection generated by
homologous rotaviruses are much stronger than those generated by heterologous
rotoviruses.
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Immune mechanisms for protection against rotavirus infection have not been clearly
established. In vitro neutralization assays and passive immunization assays with
antibodies against different rotavirus components demonstrated that VP4 and VP7 are
targets of protective immunity (Ishida et ah, 1997). However, John Bum, Harry
Greenberg and their colleagues demonstrated in a mouse “backpack tumor” model that
immunity to the non-surface capsid protein VP6 has a role in immune protection. The
investigators injected hybridoma cells producing anti-VP6 IgA antibody subcutaneously
into the back of histocompatible BALB/C mice (John et al., 1996). At the injection site,
the mice secreted monoclonal antibodies, which were subsequently transported in the
circulatory system and eventually reached the mucosal surfaces by transcytosis. The antiVP6 IgA antibody completely inhibited rotavims infection following vims challenge.
Recent identification of a rotavims nonstmctural protein NSP4, which acts as a viral
enterotoxin, may provide a new approach to induction of immune protection against
clinical rotavims disease (Ball et al., 1996; Angel et al., 1998). The nonstmctural protein
NSP4 is an intracellular receptor that mediates acquisition of a transient membrane
envelope as subviral particles bud into the endoplasmic reticulum (Superti et al., 1998;
Newton et al., 1997; Tian et al., 1996). Baculovims production of the NSP4 protein
caused an increase in intracellular calcium levels in insect host cells (Ball et al., 1996).
Purified NSP4 or a peptide corresponding to NSP4 residues 114-135 induced diarrhea in
young GDI mice. Electro-physiologic data from intestinal mucosa showed that the NSP4
peptide potentiates chloride secretion by a calcium dependent signaling pathway. Most
importantly antibody against NSP4 significantly reduced diarrheal disease in passive
immunized mouse pups (Johansen et al., 1999).
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Antibody vs cell mediated immunity in a mouse model has also been investigated.
Immunodeficient SCID mice that lack both T and B cells became chronically infected
with murine rotavirus. In contrast, |32m knock out mice that lack T cells had delayed
virus clearance but were resistant to rotavirus reinfection (Offit, 1996). When B cell
deficent JHD knock out mice were challenged with rotavirus, most of them cleared
rotavirus infection like control mice. Re-challenge of B cell deficient mice that had
completely resolved primary rotavirus infection became reinfected but shed smaller
amounts of viral antigens. This series of experiments demonstrated that both T and B
cells can clear primary rotavirus infection and protect against reinfection. T cells appear
to expedite normal virus clearance while antibodies seem to be the principal factor
mediating protection from reinfection.
Rotavirus vaccine development has passed through several developmental stages
(Orenstein et ah, 1996). First generation rotavirus vaccines used rotavirus strains from
animal origins. A live attenuated bovine rotavirus vaccine named RIT4237 was tested in
children in Finland, and yielded a 50% protection rate against all rotavirus disease and a
80% protection rate against severe rotavirus disease (Vesikari et ah, 1986). However
vaccines composed of a single animal origin rotavirus failed to consistently protect
infants in repeated clinical trials (Kapikian et ah, 1994). Thus second generation rotavirus
vaccines composed of animal rotavirus reassortants which also express human rotavirus
surface antigens were developed (Glass et ah, 1994). A bovine WC3 reassortant vaccine
expressing VP7 surface protein of human PI G1 rotavirus strain was extensively tested in
clinical trials (Clark et ah, 1988; Bernstein et ah, 1990). This vaccine gave 67% protection
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against all rotavirus disease and 87% protection against clinically significant rotavirus
disease and complete protection against rotavirus diarrhea.
With respect to the use of recombinant protein based vaccines, induction of active
immunity with individual rotavirus proteins has so far been unsuccessful. One important
reason for the lack of success is that discontinuous epitopes are crucial for induction of
protective immunity and native folding of the rotavirus proteins was not achieved with
individual soluble rotavirus proteins. Recently promising results have been obtained with
recombinant virus-like particles (VLPs) produced by co-expression of rotavirus structural
proteins in insect cells (Corsaro et al., 1996; Crawford et al., 1994; Conner et al., 1996).
Virus-like particles composed of VP2/6/7 and VP2/4/6/7 administered parenterally to
mice and rabbits induced both neutralizing and serotype-specific antibody responses in
both serum and intestine (O’neal et al., 1997). Oral inoculation of mice with rotavirus
VP2/6/7 VLPs with cholera toxin as an adjuvant, induced antibodies in both serum and
intestine. Multivalent VLP vaccines that display VP7s from two or more serotypes
induced neutralizing antibodies to homotypic and heterotypic rotavirus strains.
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CHAPTER TWO
MATERIALS AND METHODS
A. Materials
1. Reagents
All restriction endonucleases, T4 DNA polymerase, T4 DNA ligase, alkaline
phosphatase were purchased from New England Biolabs (Beverly, MA). QIAquick PCR
purification Kit, QIAquick Gel Extraction Kit, QIA quick nucleotide Removal Kit,
QIAprep Spin Miniprep Kit, QIAfilter Plasmid Midi Kit, and Omniscript Reverse
Transcirptase Kit were purchased from Qiagen Inc. (Valencia, CA). Rabbit anti-mouse
IgG, anti-mouse IgA alkaline phosphatase conjugates and mouse anti-rabbit IgG, anti
mouse IgA alkaline phosphatase conjugates were purchased from Sigma Chemical Co.
(St. Louis, MO). Monoclonal anti-mouse CD4, CD8b.2 PE conjugates, anti-mouse
CD62L FITC conjugates, and anti-mouse CD44 Cy-chrome conjugates were obtained
from (PharMingen, San Diego, CA). Antibiotics gentamycin sulfate, kanamycin
monosulfate, rifampicin carbenicillin, and ampicillin were obtained from Sigma
Chemical Co. (St. Louis, MO). Mouse interleukin-2, interleukin-4 and interferon gamma
ELISA kits were purchased from Endogen Inc. (Woburn, MA).
Oligonucleotides were synthesized using a model 394 DNA/RNA Synthesizer
(Applied Biosystems, Inc.) in the DNA Core Facility located in the Center for Molecular
Biology and Gene Therapy, Loma Linda University.
Polyclonal anti-CFA/I was generated in rabbits by Biosynthesis Inc. (Lewisville, TX)
according the following immunization protocol: two 3 month old female rabbits (New
Zealand White, approximately 3-4 kg) were injected intraderm ally and intramuscularly
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with 200-500ug purified CFA/I antigen in a 50/50 emulsion mixture with TiterMax
incomplete adjuvant on day 0, 21, 35. The immune response was boosted every two
weeks starting from week 6 untill the termination of the experiment. Serum was collected
on week 6, 8 and 10 followed by ELISA determination of anti-CFA/I titers.
Immunoaffmity purified SA11NSP4 protein, rabbit anti-NSP4 serum and the
rotavirus SA11 strain were provided by Dr. Mary Estes, Baylor College of Medicine.
Rabbit anti-rotavirus hyperimmune serum, mouse anti-VP6 serum and the plasmid PKS+
containing murine VP6 CDNA were provided by Dr. H. Greenberg, Stanford University,
School of Medicine. Plasmid pPT42 containing the cholera toxin ctxAB operon was
provided by Dr. J. Mekalanos, Harvard Medical School.
2. Animals
Adult CD-I mice (male, female) were purchased from Charles River Breeding
Laboratories, Inc. (Wilmington, MA) at 5-6 weeks of age. The animals were housed in
self-contained filter-top cages in a room controlled for temperature, humidity, and a 12 h
day-night cycle. Autoclaved bedding, food and water were provided. At the time of
sacrifice, rapid CO2 asphyxiation was performed in compliance with the NIH Guide for
the Care and Use of Laboratory Animals. All animal care was performed under the
direction of a licensed veterinarian. The animal study was approved by the Loma Linda
University Animal Research Committee.
B. Methods
1. Preparation of Electro-competent Cells
A single colony of Escherichia coli strain HB 101 was inoculated into 5ml liquid
Luria-Bertani (LB) medium (10 g/1 Tryptone, 5 g/1 Bacto yeast extract, 10 g/1 NaCl, pH
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7.3) and was grown at 37°C overnight with vigorous shaking (approximately 250 to 300
rpm). 2.5 ml of the culture was transferred into 500 ml LB medium in a sterile 2 liter
flask and was grown at 37°C with shaking to an ODeoo of 0.5 to 0.7. The cells were
chilled on ice for 15 minutes, and then were centrifuged at 5000 x g for 20 minutes. The
supernatant was removed and the cell pellet was washed twice with 500 ml ice cold
distilled water. The cell pellet was washed in 80 ml 10% ice cold glycerol and
resuspended in a final volume of 2 ml 10% glycerol. Small aliquots of 50 pi were
transferred to pre-chilled microfuge tubes and frozen on dry ice for 20 minutes. Finally,
the competent cells were stored at -80° C. Vor Agrobacterium tumefaciens strain GV3101
pMP90RK, the cells were grown at 28°C with shaking in YEB medium (beef extract 5.0
g/1, Bacto yeast extract 1.0 g/1, Bacto peptone 1.0 g/1, surcose 5.0 g/1, MgS04.7H20 0.1
g/1, pH 7.3) containing the antibiotics rifampicin (100 ug/ml), kanamycin (25 ug/ml), and
gentamycin (25 ug/ml).
2. Bacterial Transformation by Electroporation
Plasmid DNA (100-200 ng) was mixed with 50 pi E.coli or A. tumefaciens electrocompetent cells. The mixture was transferred to a 0.2 cm electroporation cuvette. The
Gene Pulser electroporation apparatus (Bio-Rad, Inc. Hercules, CA) was set at 2.5 kV, 25
uFD, 200 Q. After electroporation 1 ml SOC medium (2.0% Bacto tryptone, 0.5% Bacto
yeast extract, 10 mM NaCl, 2.5 nM KC1, lOmM MgCh, lOmM MgSCL, 10 mM glucose)
was added to the cuvette to suspend the cells. The cell suspension was transferred to a
5ml culture tube, incubated with shaking at 200 rpm for 2 hours. For E.coli 0.1 ml cell
culture was plated on LB selection medium containing ampicillin (lOOug/ml). Ampicillin
resistant colonies were isolated after overnight culture at 37°C. For A tumefaciens 0.1 ml
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cell culture was plated on YEB selection medium containing rifampicin, kanamycin,
gentamycin and carbenicillin (lOOug/ml). Carbenicillin resistant colonies were isolated
after incubation at 28°C for 48 to 72 hours.
3. A.

Mediated Plant Transformation

Potato plants Solarium tuberosum cv. Bintje were grown in sterile Magenta boxes
(Sigma Chemical, St. Louis, Missouri) on Murashige and Skoog (MS) medium (Sigma)
containing 3.0% sucrose and 0.2% gelrite. Leaves from 3-4 week old sterile shoots were
cut from the plant at the leaf base and transected in the middle of the leaf perpendicular to
the midvein. The leaf fragments were immediately transferred and immersed in 10 ml
overnight culture of A. tumefaciens suspension (2-5 x 109 cells/ml) carrying the plant
expression vector with the desired genes inserted between the T-NDA borders.
Acetosyringone (370 pM, final concentration) was added to the bacterial suspension to
facilitate transformation. The leaf explants were incubated in the bacterial suspension for
5-10 min, blotted damp dry on sterile filter paper and transferred upside down to callus
medium (MS medium, 0.1 pg/ml naphthalene acetic acid (NAA), 1.0 pg/ml trans-zeatin,
pH 5.7). The leaf explants were incubated for 2-3 days at room temperature to permit the
transfer of T-DNA into plant genome. The infected leaf discs were washed in sterile
distilled water containing claforan (300 pg/ml), blotted dry on sterile filter paper and
placed inverted on callus selection medium ( callus medium, kanamycin 100 fag/ml,
claforan 400 pg/ml), for selection of transformed plant cells and selection against A.
tumefaciens. The explants were incubated in the light room for a period of 3-4 days, then
transferred to fresh plates and incubated for another 3-4 weeks to permit callus growth at
the wound surfaces. Leaf explants containing the green and friable callus tissue were
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transferred to shoot growth medium (MS medium, 1.0 |ug/ml trans-zeatin, 50 jug /ml
kanamycin, 400 jag/ml claforan) and incubated for additional 2-3 weeks to facilitate shoot
formation. Potato shoots approximately 0.5 cm long were removed from the callus tissue
and transferred to root induction medium (MS, 300 pg/ml claforan) for root formation.
The transgenic plantlets were obtained after 4-6 weeks further growth under sterile
conditions. The plantlets were transferred to potting soil and grown into mature tuber
bearing plants in the greenhouse.
4. Analysis of DNA/RNA from Transformed Plants
Plant genomic DNA was isolated from transformed potato leaf tissues using the
Dneasy Plant Mini Kit (Qiagen Inc.) Presence of the gene inserts was determined by
Polymerase Chain Reaction (PCR) analysis. The PCR reaction mixture contains: plant
genomic DNA (400 ng) as templates, 5’ and 3’ primers (100 pmol each) specific for the
gene inserted, 10 pi thermo-buffer, 2 pi dNTP mixture (10 mM each), 0.5 pi (lunit) Vent
DNA polymerse (New England, Biolabs). Distilled water was added to a final volume of
100 pi. The reaction mixture was put under the following PCR conditions: DNA melting:
94°C for 45 sec, primer-DNA annealing: 55°C for 60 sec, and primer extension: 72°C for
60 sec for a total of 30 cycles.
Total RNA from leaves of transformed plants was isolated using Rneasy Plant Mini
Kit (Qiagen Inc.) the presence of mRNA transcribed from the inserted genes was
determined by reverse transcription PCR (RT-PCR) analysis following the instructions of
the Omniscript Reverse Transcirptase Kit (Qiagen Inc.). The reverse transcription (RT)
reaction mixture contains: total RNA extraction (100 ng) from transformed plants as
templates, 2 pi RT buffer (Qiagen Inc.), 2pl dNTP (5mM each), Ipl (4 units) reverse

30

transcriptase, Ipl 3’ primer (Ipmol) specific for the gene inserted. RNase-free water was
added to make a final volume of 20 pi. The RT reaction mixture was incubated at 37°C
for 60 min followed by heat inactivation at 93°C for 5 min. The RT reaction mixture was
used as templates in the following PCR reaction: 5’ and 3’ primers (100 pmol each)
specific for the gene amplified, 2pl dNTP mixture (10 mM each), 10 pi thermo buffer
(Qiagen Inc.), 0.5 pi (1 unit) Taq DNA polymerase (Qiagen Inc.). The reaction was
performed in the following PCR cycle: 94°C for 45 sec, 55°C for 60 sec, and 72°C for 60
sec for a total of 34 cycles. This was followed by final extension of 10 min at 72°C. The
reaction was then cooled to 4°C. PCR and RT-PCR samples were separated by
electrophoresis on a 1% agarose gel and stained with ethidium bromide.
5. Western Blot Analysis of Antigen Gene Expression in Plant Cells
Potato leaves and tuber slices from the transformed plants were incubated at room
temperature for 5-7 days on MS medium containing NAA (5.0 mg/1) and 2,4-D (6.0
mg/1). Incubation on high auxin medium for at least 4 days is necessary to detect the
maximum amount of gene expression from the mas promoters in potato plant tissues.
Approximately 1.0 g of potato tissues were homogenized by grinding in a mortar and
pestle on ice in 1 ml extraction buffer (200 mM Tris-HCl, pH8.0, lOOmM NaCl, 400mM
sucrose, lOmM EDTA, 14 mM 2-mercaptoethanol, ImM phenylmethylsulfonyl fluoride,
0.05% Tween-20). The tissue homogenates were centrifuged twice at 17,000 x g for 15
min at 4°C to remove insoluble cell debris. An aliquot of 10-20 pi supernatant, containing
100-200 pg of total soluble protein, as determined by Bradford protein assay (Bio-Rad,
Inc.), was separated by 10%- 12% sodium dedecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) at 100 V for 60 min in Tris-glycine buffer (25 mM Tris,
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250 mM glycine, pH 8.3, 0.1% SDS). Samples of the plant homogenate were either
boiled 5 min prior to electrophoresis or loaded directly on the gel.
The separated protein bands were transferred from the gel to nitrocellulose
membrane (MSI Inc.) by electroblotting on a semi-dry blotter (Sigma Chemical Co.) for
90 min at 30 V and 60 mA. Nonspecific antibody binding was blocked by incubation of
the membrane in 5% non fat dry milk in TBS buffer (20 mM Tris, pH7.5, 500 mM NaCl)
for Ihour on a rotary shaker (40 rpm), followed by washing once in TBS buffer for 5
min. The membrane was incubated overnight at room temperature with gentle agitation in
20 ml of a primary antibody in TBST buffer (TBS, 1% non fat dry milk, 0.05% Tween20) followed by washing three times in TBST buffer. The membrane was incubated for
Ih at room temperature in 20 ml alkaline phosphatase conjugated secondary antibody in
TBST buffer. The membrane was then washed three times in TBST buffer and one time
with TBS buffer. Finally the membrane was incubated in the substrate BCIP/NPT
(Sigma) for lOmin. The color reaction was stopped by washing the membrane several
times in distilled water.
6. Chemiluminescent ELISA
The amount of plant-synthesized CTB-NSP4 fusion protein was measured in
transformed plant extracts by chemiluminescent Gmi ELISA assay. The wells of a 96well microtiter plate (Dynatech Laboratories) were coated with 100 pl/well of
monosialoganglioside Gmi (3.0 pg/ml) (Sigma) in pH 9.6 bicarbonate buffer (15mM
Na2C03, 35mM NaHCOs), and incubated at 4° C overnight. The plate was washed three
times with PBST (phosphate buffered saline (PBS) containing 0.05% Tween-20). The
background was blocked by incubation in 1% bovine serum albumin (BSA) in PBS (300
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I^l/well) at 37° C for 2h followed by washing three times with PBST. The microtiter plate
was incubated with 2 pg of transformed plant total soluble protein per well in PBS (100
pl/well). For use as a positive control, a known amount of bacterial CTB (Sigma) plus 2
pg untransformed plant total soluble protein in PBS (100 pl/well) was added to the plate
and incubated overnight at 4° C. The plate was washed three times with TBST and then
incubated in a 1:8000 dilution of rabbit anti-cholera toxin antibody (Sigma, 100 pl/well)
for 2h at 37° C, followed by washing three times with PBST. The plate was incubated
with a 1:80,000 dilution of anti-rabbit IgG alkaline phosphatase conjugate (Sigma, 100
pl/well) for 2h at 37° C and washed three times with PBST. The plate was finally
incubated with 100 pl/well Lumi-Phos Plus substrate (Lumigen) for 30 min at 37° C. The
plate was cooled for 5 min and light emission was measured in a Dynatech 3000
Microtiter Plate Luminometer (Dynatech Laboratories).
The amount of plant-synthesized CFA/I-CTA2 fusion protein in each well was
measured by the same chemiluminescent ELISA assay with the exception that 2ug of
transformed plant total soluble protein was directly coated on the plate in pH9.6
bicarbonate buffer. The first antibody used was rabbit anti-CFA/I at a 1:3000 dilution.
The rest of the assay procedure was identical to the ELISA described above.
The expression level of plant synthesized VP6 was quantified by chemiluminescent
sandwich ELISA. A 96 well microtiter plate was coated with mouse anti-VP6 serum
diluted 1:1,000 in bicarbonate buffer (pH 9.6) at 4°C overnight. The plate was blocked
with 1% BSA in PBS buffer at 37°C for 2 hours. Protein extracts from transformed potato
tuber tissues were added to the wells and incubated overnight at 4°C. Known amount of
purified virus VP6 mixed with protein extracts from untransformed potato tuber tissues
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were added to the wells as standard curves. The plate was incubated with rabbit anti
rotavirus serum diluted 1:2,000 in PBS buffer and then incubated with mouse anti-rabbit
IgG conjugated with alkaline phosphate in 1:80,000 dilution in PBS buffer. The plate was
finally incubated with chemiluminescent substrate, Lumi-phos Plus (Luminogen, Inc.) for
30 minutes at 37°C, and the plate was read in a Microtiter Plate Luminometer (Dynatech).
Light emission was recorded as relative light units (RLU) over the background.
7. Mice Oral Immunization
Adult CD-I mice were fasted overnight before each oral immunization. On each
feeding day, 10 pg of purified bacteria cholera toxin (Sigma) was first administered as an
adjuvant to the mice in 0.4 ml sodium bicarbonate buffer (350 mM, pH 8.5) by gastric
intubation (gavage). The mice were then fed 3-5 g (fresh weight) transgenic potato tuber
slices containing 10-20 fig of plant produced VP6, CFA/I or CTB-NSP4 antigens,
previously determined by ELISA assay. A group of CD-I mice were fed same 3-5 g of
untransformed potato tuber slices to serve as negative control. Mice fed the same amount
of purified rotavirus VP6 or NSP4 proteins served as positive controls. On day 23 after
the final immunization, the mice were euthanized by CO2 anoxia. Blood samples
collected from each mouse were incubated at room temperature for 4-5 hours followed by
overnight incubation at 4°C to retract blood clots. The blood samples were centrifuged at
4°C, 2,800 x g for 10 minutes. The supernatants were removed from the red blood cells
and centrifuged for another 10 minutes at 4°C 4000 x g. NaN3 was added to the obtained
sera to a final concentration of 0.03%. The sera were stored at room temperature. The
small intestines of the sacrificed mice were removed and the lumen of the intestine was
washed with 1 ml PBS buffer, pH 8.5, containing 10 mM PMSF. The intestinal wash was
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centrifuged twice at 4°C 5000 x g for 10 minutes. The supernatant was immediately
analyzed by ELISA for intestinal antibodies or stored at -80°C.
8. Production of Passively Immunized Mouse Pups
Female CD-I mice were fed 3-5 g transgenic potato tuber slices, containing plantsynthesized antigens, once a week for four weeks. Immediately following the fourth
immunization at maximum antibody titer, each immunized female was paired with one
uninfected male. Successful mating was detected by the presence of a copulatory plug in
the vagina 24 hours after mating. The male CD-I mice were separated from the females
after mating. After 19-21 days gestation period, mouse pups were bom with a litter size
of 8-12 pups. The pups remained with the dams until the day of vims inoculation.
9. Rotavims Challenge of Suckling Mice
Protection of NSP4 antibodies against rotavims induced diarrhea was evaluated by
rotavims challenge of passively immunized mouse pups. Six day old suckling mice were
orally gavaged with SA-11 rotavims suspension. Each pup received one oral dose that
contained 15 x DD5o (vims dose determined empirically to cause diarrhea in 50% of the
mouse pups) in 50 pi of endotoxin-free PBS. Vims inocula were not trypsin-activated
prior to inoculation. All cages were coded and individual mice were checked for diarrhea
daily for 7 days after inoculation by gentle palpation of their abdomen. A diarrhea score
and the proportion of mice with diarrhea in each study group was recorded. Stool
classification was defined as: 0, no stool; 1, normal stool; 2, normal stool accompanied
with yellow pasty stool; 3, all yellow pasty stool; 4, milky-liquid stool. The pups with a
stool score > 2 were considered to have diarrhea.
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10. Cytokine Analysis in Spleen Cells
Orally immunized mice were killed at three different time points: 13, 34 and 68 days
after the final immunization. A spleen cell suspension was prepared by gently pressing
spleen tissue through a fine nylon mesh sieve. The suspension was washed in RPMI-1640
medium once by centrifuging at 800 x g, room temperature. The cell pellet was
resuspended in complete media (RPMI-1640, 10% fetal calf serum and 1%
penicillin/streptomycin), counted with a Unopette hemocytometer (Becton Dickinson,
NJ) and put into 24 well tissue culture plates (3 x 106 cells/well) in duplicate samples.
After incubation for 72 h at 37°C in a humidified, 5% CO2 incubator, supernatants from
the spleen cell cultures were collected for assessment of IL-2, IL-4 and IFNy secretion.
Assay procedures followed the instructions of the cytokine ELISA kits (ENDOGEN,
MA). Briefly, standard sandwich ELISA technique utilizing capture antibody and
enzyme-conjugated detection antibody were employed. Cytokines of known
concentrations were included in each assay to produce standard curves. Standards and
samples were assayed in duplicates to assure reproducibility. Plates were read in a Mark
II Plate Reader (Dynex Technologies Inc, VA).
11. Flow Cytometry Analysis
Spleen lymphocytes were stained with fluorochrome-labeled monoclonal antibodies
(mAh) for immunophenotyping. Two monoclonal antibody panels were constructed for
three color analysis (fluoresceinisothiocanate (FITC), phycoerythrin (PE), and CyChrome). The first combination used, CD62L*FITC/CD4*PE/CD44*Cy-Chrome,
designates naive and memory T helper cells. The second combination,
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CD62L*FITC/CD8b.2*PE/CD44*Cy-Chrome, designates naiVe and memory cytotoxic T
cells.
Spleen cells were adjusted to lx 106/ml or 3x 106/ml. One hundred microliters of
cells were aliquotted into 5 ml tubes and incubated 15 minutes on ice with the desired
monoclonal antibody. Samples were lysed with 2 ml lysing buffer (0.8% Tris ammonium
chloride) while vortexing, then incubated 6 minutes at room temperature. Samples were
spun at 400 g for 5 minutes, aspirated, resuspended in 200 pi PBS (Cellgro, San Diego,
CA) and placed on ice until acquisition in the flow cytometer. Cells were acquired and
analyzed on a Fluorescence-Activated Cell Sorter with Consort 32 software (FACSort,
Becton Dickinson, San Jose, CA). A minimum of 1000 events was acquired for analysis
using quadrant plots. Analytical controls included unstained cells to assess the degree of
auto fluorescence.
3.

Statistical Analysis

The data were analyzed using one-way ANOVA and student’s t test. A P value of <
0.05% was considered to indicate significant differences among different immunization
groups.
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Abstract
Advances in genetic engineering throughout the past decade have accelerated the
expression of foreign proteins with industrial and pharmaceutical value in plants.
Antigens obtained from infectious bacterial or viral diseases have been introduced into
plants through plant virus mediated transient transformation or Kgrobacterium
tumefaciens mediated stable transformation methods. The plant produced vaccine
antigens were found to retain their antigenicity. Oral immunization with transgenic plant
tissues containing vaccine antigen proteins stimulates both systemic and mucosal immune
responses in animals. Plant-based vaccines can provide significant levels of protection
against challenge by viral or bacterial pathogens.
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1. Introduction
The engineering of plants, traditional sources of food, fiber and energy has been
practiced for decades, and has led to major accomplishments in the improvement of
agricultural properties such as insect and disease resistance, tolerance to high salinity,
drought, increased tolerance to pesticides and herbicides and extraction of toxic metals
from the soil. Recent advances in molecular biology have facilitated the production in
plants of foreign proteins of high therapeutic value. In 1992, Amtzen and his colleagues
introduced the concept of transgenic plants as vaccine production systems [1]. Additional
experiments in several laboratories have demonstrated that bacterial and viral antigens
can be expressed in a variety of plant species [Table 1]. Oral or parenteral administration
of plant derived antigens generated systemic and mucosal immune responses indicating
that transgenic plants have great potential for the development of oral vaccines [2-7].

2. Advantages of Plant Vaccines
Plant-based vaccines have attracted the attention of the pharmaceutical industry
for safety and economic reasons. For example, proteins isolated from plant tissues are
free from animal pathogenic contaminants and plant pathogens are not infectious for
humans. In addition, plants do not generate similar metabolic products, which can co
purify with the transgene product of interest. Plant cultivation is straightforward and
inexpensive making use of indigenous agricultural techniques and available agricultural
machinery. Scale up for agricultural production can be achieved at minimal cost
compared with conventional fermentation methods. Of greatest importance, plant cells
like other eukaryotic cells, can perform post-translational modifications e.g.,
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glycosylation and phosphorylation essential for the biological activity of proteins of
animal origin [8]. Transgenic plants can be conveniently stored and distributed in the
form of tubers and seeds. Administration of plant vaccines can be as sample as eating,
requires no needles or trained personnel. All these benefits may make it possible for
global vaccination programs to effectively control endemic diseases that take a huge toll
of life, mostly children, in rural populations of the developing world.

3. Production of Antibodies in Transgenic Plants for Passive Immunization
The first case of antibody production in transgenic plants was demonstrated by
Hiatt in 1989 [9]. The gamma and kappa chains of immunoglobulin were expressed
separately in tobacco plants. Crossing the two plants resulted in simultaneous expression
of both chains, which self assembled into functional antibodies. The presence of a leader
sequence increased the accumulation of functional antibodies to 1.3% of total leaf
protein. Various strategies have been applied to improve antibody yields in plants.
Genetic fusion of the endoplasmic-reticulum retention signal KDEL to antibody
fragments increased the single chain Fv protein yield up to 4%- 6.8% of total soluble
protein [10]. So far, the most complex antibody assembled in plants was the recombinant
secretory immunoglobulin, Guy’s 13 [11]. This secretory antibody is composed of a
murine joining (J) chain, a rabbit secretory protein component (SC), a kappa protein
chain and a hybrid IgA-G antibody heavy chain. The Guy’s 13 secretory antibody
recognizes the streptococcal adhesion molecule (SAI/II) of Streptococcus mutans, which
is the major cause of dental caries. In his experiments, Julian Ma generated four
transgenic Nicotiana tabacum plants, each of which expressed one of the four different
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parts of Guy’s 13 secretory antibody. A series of sexual crosses between these plants and
filial recombinants generated a plant progeny that expressed all four protein chains
simultaneously [11]. Efficient assembly of these immunoglobulin chains produced a
functional secretory antibody with a molecular weight of approximately 470 kDa.
Enzyme linked immunosorbent assay (ELISA) showed its antibody function to
specifically recognize the SAI/II antigen. Production of a complex secretory antibody in a
plant and retention of biological function demonstrate the amazing capability that plants
have to synthesize and assemble complex biomolecules for human applications. The plant
produced SIgA has great applications for passive immunotherapy.

4. Plant-based Vaccines for Protection against Infectious Diseases
Many infectious agents come in contact with the host at the surface of epithelial
membranes. The mucosal immune response in the gastrointestinal, respiratory and
urogenital tracts form the first line of defense against a variety of infectious diseases. The
mammalian mucosal immune system is an integrated network of tissues, cells and
macromolecules. Secretory IgA as an effector molecule plays an important role in
neutralizing bacterial or viral toxins, inhibiting pathogen colonization and eradicating
bacterial or viral antigens from the circulatory system. Vaccination by oral administration
of an antigen protein is more efficient than parenteral inoculation for induction of
mucosal immune responses. Attempts to induce mucosal immunity by oral delivery of
live attenuated bacterial or viral strains have met with limited success. Plant vaccines,
which protect antigens from intestinal digestion, offer a safe and effective alternative.
Two strategies have been pursued to develop plants as vaccine production and delivery
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systems. The first is the Kgrobacterium tumefaciens mediated stable transformation
system, which is based on stable integration of foreign DNAs into the plant genome. The
integrated genes are passed from one generation to another at expression levels ranging
generally from 0.01% to 0.4% of total plant soluble protein. The second method for
synthesizing vaccine proteins in plant cells is based on plant virus mediated infection,
which provides a higher yield of vaccine antigens, up to 2.0% of total plant soluble
protein within weeks after infection rather than months required for stable transformation
methods. Virus infection kills the plants which requires reinfection with virus for each
vaccine harvest. The viral products can’t be used directly for vaccination but require
purification from infected plant tissues.

5. Transient Antigen Expression in Plants
Plant viruses can replicate to high levels in infected plant tissues, up to 50% of total
soluble plant proteins. There are generally two approaches in which modified plant
viruses have been used for synthesis and accumulation of recombinant proteins in plants.
In the first case, the foreign genes are transcribed from viral promoters, which produce
soluble antigen proteins during virus infection. The second case involved the
modification of viral capsid proteins to carry vaccine epitopes. Due to the expression of
multiple copies of antigen on the surface of a virus particle, this method has been the
most used one.
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a. Tobacco Mosaic Virus (TMV)
TMV is a rod-shaped RNA plant virus composed of approximately 2100 identical
capsid proteins. Structural studies of the virus particle identified loop regions on the
capsid protein that are unlikely to interfere with virus assembly or viral infection. These
loops were targeted with foreign antigens. In one example, an HIV epitope of 20 amino
acid residues was inserted into the TMV capsid protein loop. Infection of N. tabacum
plants with the modified virus led to accumulation of the chimeric capsid proteins [12].
Immunoblot and ELISA data indicated that the correct expression of the epitopes is
located at the surface of the viral particle. Turpen et al. (1995) described the expression
of a malarial sporozooite antigen epitope in TMV using the same strategy [13],

b. Cowpea Mosaic Virus (CPMV)
CPMV is an RNA virus containing 60 copies of a large (L) and a small (S) protein
subunit. Potential insertion sites of foreign protein sequences were determined by
extensive analysis of the 3-dimensional structure of CPMV. An epitope derived from
VP1 of foot and mouth disease virus (FMDV) was cloned into one particular loop region
of the S protein [14,15]. The chimeric RNAs were able to replicate in cowpea protoplasts.
FMDV-specific antiserum recognized the modified S protein. Immunosorbent electron
microscopy identified the assembly of the virus particle in cowpea plant leaf tissues.
However, serial passage of recombinant CPMV revealed rapid loss of the inserted
sequence. Genetically more stable chimeric CPMV particles that express epitopes derived
from human rhino virus 14 and human immunodeficiency virus (HIV-1) were described
by Porta et al. in 1994 [16]. The inserted epitopes were immunogenic in rabbits. The
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CPMV expression system was successfully used for animal vaccination. Dalsgaard and
his colleagues reported insertion of a linear epitope from the VP2 capsid protein of mink
enteritis virus (MEV) into CPMV particles [17]. Virus particles harvested from blackeyed bean plants were used for subcutaneous injection in mink. A considerable reduction
of virus shedding was detected after challenge with virulent MEV. This was the first
experiment to demonstrate that a plant vaccine protects against an infectious disease in
target animals.
TMV and CPMV are the most commonly used viruses for the generation of
plant-based vaccines due to their wide host range. Research on other plant viruses has
also showed promising results. For example, the coat protein of alfalfa mosaic virus was
fused with peptides from rabies virus and HIV [18]. The plant produced antigens elicited
specific neutralizing antibodies against rabies virus and HIV in immunized mice. In their
study 40% of the mice were protected against a lethal dose challenge of rabies virus.
However, despite the high vaccine protein yield of the virus system the size of the
antigenic epitope that can be attached to or inserted into the virus capsid protein is small.
Less than an 80 amino acid sequence has been inserted successfully into the virus without
disrupting the viral particle formation. From a clinical perspective, expression of a single
epitope in a plant may not provide full protection against the infectious disease.

c. Stable Expression of Antigens in Plants
The surface antigen (spa-A) from Streptococcus mutans was the first vaccine
candidate to be stably expressed in plants [19]. The spa-A protein is 18.5 kDa in size and
is composed of over 1500 amino acids. In comparison with the virus expression systems,
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Agrobacterium mediated transformation overcomes the size limitation of recombinant
proteins which can be synthesized in plant cells. One of the first vaccines generated by
stable transformation methods in plants was the Hepatitis B virus, a major cause of
human acute and chronic Hepatitis. The Hepatitis B surface antigen (HBsAg) was
expressed in tobacco plants at levels about 0.01% of total soluble protein [1], The
tobacco-derived HbsAg forms subviral particles of 22 nm in diameter in the plant, which
are the size found in infected human serum. Parenteral immunization of purified antigen
stimulated both B and T cell immune responses in mice, similar to that found for
commercial Hepatitis B vaccine derived from yeast [20]. These experimental results
proved the concept of low cost plant vaccines.
Driven by the need to develop cheap oral vaccines applicable for the developing
world, current plant vaccine research is targeting pathogens that cause infectious enteric
diseases. Enterotoxigenic E.coli (ETEC), cholera, rotavirus and Norwalk virus are the
four leading causes of epidemic gastroenteritis in humans. Diarrhea caused by these
bacteria and viruses accounts for approximately three million infant deaths per year,
mostly in the developing world. In United States alone, the direct and indirect health
costs exceed one billion dollars per year.
Cholera is a devastating diarrheal disease that has caused recurrent pandemics
throughout the world since 1871. The cholera toxin (CT) from Vibrio cholerae is one of
the most potent mucosal immunogens yet identified. This enterotoxin is composed of
one A subunit (CTA) and five identical B subunits (CTB) [21]. The A subunit harbors
ADP transferase activity. The CTA subunit binds to the adenylate cyclase in the cell
resulting in massive secretion of sodium, chloride and water from the blood into the
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intestinal lumen. Five copies of the B subunit form a pentameric ring like structure,
which binds to GM1 gangloside receptors present in the gut epithelial cell membranes. In
1998, Arakawa et al. expressed the CTB subunit in potato plants [22]. An ER retention
signal (SEKDEL) fused to the 3 ’ end of the CTB gene facilitated accumulation of CTB
gene products in the plant cells. The expression level was 0.3% of total soluble protein.
The synthesized CTB subunits formed CTB pentamers, which retained GM1 ganglioside
binding affinity. Oral feeding of 3.0g of transgenic potato tubers induced both serum and
intestinal CTB-specific antibodies in mice [23]. More importantly, the immune response
against CTB could be boosted significantly by a single additional oral dose. Ileal loop
assays demonstrated a 60% reduction in fluid accumulation in the small intestine of
immunized mice. In addition to its mucosal immunogenicity, CTB has mucosal adjuvant
activity, which is largely attributed to its cell binding properties [24,25]. More recently,
CTB was found to be useful as a carrier molecule for specific targeting to the gut
associated lymphoid tissues (GALT). A CTB-insulin fusion protein produced in
transgenic potato plants successfully protected nonobese diabetic mice from development
of antoimmune diabetes mellitus Type I [26].
Enterotoxigenic E. coli (ETEC), is the most common causative agent of travelers’
diarrhea. Present estimations indicate that 50% of persons traveling to developing
countries experience diarrheal disease and ETEC has been isolated in 33 to 50% of these
episodes. ETEC strains possess two pathogenic traits: adhesion to the small intestine and
production of a heat labile enterotoxin (LT). The LT is structurally, functionally and
antigenically similar to CT. Both toxins share 80% homology in DNA sequence [21]. The
binding subunit of the ETEC heat-labile enterotoxin (LTB) has been expressed at low
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levels, 0.01% of total protein in potato plants [27]. A plant-optimized synthetic gene
encoding the LTB gene has been introduced into potato plants. The expression level was
raised to 0.15% of total soluble plant protein. As expected, the plant derived LTB
stimulated a mucosal immune response in mice. The immunized mice were partially
protected against bacterial LT challenge. The plant vaccine test was later moved into
human clinical trials [28]. Raw potato tubers (50g to lOOg) containing 0.5 or l.Omg plant
produced LTB were consumed by volunteers on day 0, 7 and 21. The volunteers
developed both serum and mucosal immune response against LTB. These results
demonstrated for the first time that food plant-based vaccines are immunogenic in
humans.
Norwalk virus is known to cause acute gastroenteritis in humans. The virus
particle is composed of a single capsid protein. The capsid proteins expressed in tobacco
and potato plants self assembled into virus like particles (VLP) [29]. The plant derived
VLPs were morphologically and antigenically similar to authentic virus particles. Mice
fed 50ug of plant produced NVCP developed serum IgG specific for Norwalk virus-like
particles. These results point the way to a new strategy for development of plant vaccines.
Since individual soluble protein antigens are often ineffective for oral immunization. This
result is probably due to intestinal digestion and lack of tropism for gut associated
lymphoid tissues. VLPs are stable in the acidic environments of the stomach, and
resistant to enzyme digestion in the small intestine. Of most importance, the VLPs
preserve conformational epitopes located on the surface of virus particles which can be
recognized by the host immune system. In comparison with other viral antigens, the plant
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produced VLP may be the most effective antigen found for protection against infectious
enteric viral diseases.

6. The Future of Plant-based Vaccines
Research efforts focused on plant vaccine development have expanded over the
past ten years. Bacterial and viral antigens have been successfully synthesized in an
increasing number of plant species. Preclinical trials have demonstrated that mammals
can be significantly protected against infectious diseases by plant synthesized vaccines.
However, many basic questions have not been adequately addressed. Low expression
levels of antigen proteins in edible plants remain as one persistent obstacle to successful
plant-based vaccine application. A variety of strategies are available to solve this
problem. For example, genes encoding vaccine antigens can be optimized for maximum
plant codon usage [28], plant promoters can be engineered to increase transcription
levels; RNA splice sites and intron sequences can be removed, 5' and 3' untranslated
regions that increase mRNA stability can be used; 5' leader sequences and 3' ER and
vacuolar retention signals can be added to increase accumulation of antigen proteins in
specific cell organelles.
Constitutive expression of foreign genes may lead to accumulation of foreign
proteins to toxic levels in the plant. Alternatively, inducible promoters, which stimulate
gene expression at specific times during plant development, may not only prevent
accumulation of toxic levels of the foreign gene product but will also conserve the plants
photosynthate for generation of maximum plant growth resulting in higher yields of
recombinant proteins [22,26]. Thus, organ and tissue specific promoters activated only in
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the fruit, tubers or seeds must be explored [30]. The cholera toxin B subunit, which
targets GM1 ganglioside receptors on the epithelial cell surface, can be used as a carrier
molecule for delivery of antigens to the gut associated lymphoid tissues [31]. Due to its
size, plant genomes can accommodate large numbers of foreign genes. Therefore it may
be possible to express several bacterial and viral antigens in one transgenic plant. Multicomponent edible plant vaccines providing immunological protection simultaneously
against several infectious diseases are currently under construction in our laboratory at
Loma Linda University. However the protective efficacy of these vaccines against
multiple antigens is still unknown.
Many pathogenic enteric viruses are composed of more than one capsid protein.
The correct assembly of double or triple layered VLPs has been achieved in bacterial or
insect cell systems. However, assembly of multi-layered VLPs in plants remains to be
detected. The production of complex VLPs in transgenic plants will provide
conformational epitopes with superior protective efficacy against pathogen challenge.
The area of plant vaccine development is in its infancy and many research experiments
remain to be done to move from the “proof of principle” stage to successful
commercialization.
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Table 1. Plant Produced Recombinant Proteins
Recombinant
proteins
Spa A of S. mutans
Hepatitis B surface
antigen
Secretory Ig A
E. coli LTB
Cholera toxin B subunit
Norwalk virus capsid
protein
Rabies glycoprotein
FMDV (foot and mouth
disease virus), VP1
FMDV, VP1

Plant host

Transformatio
n vector

Expression level

Tobacco
Tobacco

agrobacterium
agrobacterium

tobacco
Tobacco
Potato
Potato
Tobacco
Potato
Tomato
Arabidoposis

agrobacterium
agrobacterium

200-500ug/g
0.01%
0.15%

agrobacterium
agrobacterium

0.3%
0.23%
0.37%

agrobacterium
agrobacterium

0.001%
NA
NA

10-40%*
1.2-1.5mg/g*

Cowpea

Rabies virus epitope

Spinach

MEV (mink enteritis
virus), VP2
HIV, gpl20
rhinovirusl4, VP1

Black-eyed bean

Cowpea
mosaic
virus (CPMV)
Tobacco mosaic
virus (TMV)
CPMV

Tabacco
Cowpea

TMV
CPMV

NA Not applicable
* Yield of chimeric vims

55

0.02%

0.01%

NA
l-2mg/g*
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Abstract

One of the most significant problems challenging the protective efficacy of plant
delivered oral vaccines is the relatively low level of antigenic proteins generally
synthesized in plant tissues. To circumvent this difficulty, we explored the feasibility of
using cholera toxin as an enterocyte targeted carrier molecule for delivery of multiple
antigens to the mucosal immune system. Potato plants were engineered to synthesize two
cholera toxin fusion proteins. The cholera toxin B subunit (CTB) was linked to a
rotavirus enterotoxin NSP4 epitope and the cholera toxin A2 subunit (CTA2) was fused
to the enterotoxigenic E.coli (ETEC) colonization factor CFA/I. The fusion proteins were
detected in transformed tuber tissues by immunoblot assay and quantitated by enzyme
linked immunosorbent assay (ELISA). The CTB-NSP4 protein expression level was
found to be approximately 0.01% of total soluble plant protein (TSP) and the CFA/ICTA2 protein expression level was about 0.002% of TSP. Assembly of the CFA/I-CTA2
subunit with the CTB-NSP4 pentamer was detected by immunoblot and Gmi ELISA
methods. The CFA/I-CTA2-CTB-NSP4 pentamer fusion protein complex retained its
binding affinity for Gmi ganglioside enterocyte membrane receptors. Our experimental
results demonstrate for the first time that cholera toxin A and B subunit fusion proteins
synthesized in planta interact in a coordinated fashion to generate a multimeric carrier
complex for targeted delivery of multiple antigens to the mucosal surface.
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1. Introduction
Cholera, rotavirus and ETEC are three major causes of acute gastroenteritis
worldwide [1]. Vaccination and eventually eradication of these endemic diseases depends
on the development of inexpensive oral vaccines accessible to the developing world.
Recombinant DNA technology has now made it possible to express foreign antigens in
plants for creating food plant based vaccines [2,3,4,5]. Recent examples are the
expression of hepatitis B surface antigens in potatoes and tobaccos [6,7], heat sensitive
enterotoxin (LTB) expression in potatoes [8,], and Norwalk virus capsid protein in both
tobacco and potatoes [9]. However, oral immunization requires a relatively large dose of
antigen to stimulate an efficient immune response due to intestinal digestion and dilution
of the antigen by food and mucosal secretion [10]. The generally low expression level of
foreign proteins in plants is currently a limiting factor in practical application of
transgenic plants as production and delivery vehicles for oral vaccines. One attractive
solution to the necessity for antigen overproduction in plants is the development of
carrier molecules, which can target fusion antigens to the mucosal immune system.
Cholera toxin is such a carrier molecule, which possesses strong immunogenicity as well
as strong adjuvant activity [11,12,13]. Cholera toxin is made of 5 copies of the CTB
subunit and one copy of the CTA subunit. The CTB subunits assemble to form
pentameric structures, which bind to Gm i ganglioside receptors embedded in the surface
of intestinal epithelial cells. The CTA subunit is postranslationally cleaved into A1 and
A2 subunits. The small helical CTA2 subunit is inserted into the central core of the CTB
pentamer and becomes linked to the CTA1 subunit by hydrogen and disulfide bonds.
Chemically or genetically fusing small molecules to the CTB subunit was found to

58

stimulate antibody production against both antigens [14,15]. Alternatively, replacement
of CTA1 with streptococcal adhesion protein was found to stimulate an immune response
against the fusion protein [16]. In this report we demonstrate the expression of two fusion
protein genes in potato plants: a twenty two amino acid epitope of rotavirus nonstructural
enterotoxin protein NSP4 linked to the cholera toxin CTB subunit, and the ETEC fimbrial
colonization factor CFA/I fused to the cholera toxin CTA2 subunit. Further, we
demonstrate the assembly of the two fusion proteins in the plant to generate a
multicomponent cholera toxin-like structure.

2. Materials and Methods
a. Construction of Plant Expression Vectors
In our first plant expression vector construct, the CTB gene including its leader peptide
was PCR amplified from the ctxAB operon in plasmid pPT42 (provided by J. Mekalanos,
Harvard Medical School). The 3’ primer was designed to contain an oligonucleotide
encoding the endoplasmic reticulum (ER)-retention signal in frame downstream of the
CTB gene. The amplified DNA fragment encoding the CTB:SEKDEL fusion gene was
inserted into the plant expression vector pPCVTOl under control of the mannopine
synthase (mas) P2 promoter. The plant expression vector was designated pPCV701-CTB.
In a second construct, the CTB gene and its leader peptide was generated by PCR
amplification of the same ctxAB operon. The 3 ’ primer was designed to contain a
nucleotide sequence encoding the tetrapeptide hinge (Gly-Pro-Gly-Pro) to increase the
flexibility of the conjugated protein. The CTB:hinge sequence was inserted into plant
transformation vector pPCVTOl under control of the mas P2 promoter. The plant
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expression vector was designated pPCVTOl CTBH. A double stranded DNA fragment
encoding the rotavirus enterotoxin NSP4 (114-135) epitope was synthesized in a model
394 DNA/RNA Synthesizer (Applied Biosystems, Inc.). The 3’end of the NSP4 sequence
contains the ER retention signal, SEKDEL. The NSP4:SEKDEL sequence was cloned
into plant expression vector pPCV701CTBh, immediately downstream of the CTB: hinge
sequence to create the fusion gene CTB:hinge-NSP4:SEKDEL. The plant expression
vector was designated pPCV701CTB-NSP4.
In a third construct, The CTA leader sequence and CTA2 gene, which contains its
own KDEL signal sequence was amplified by PCR from the ctxAB operon, and inserted
into the vector pPCV701 CTB-NSP4 under control of the mas PI promoter. A DNA
fragment encoding the ETEC colonization factor CFA/I was amplified from plasmid
pIGxl5A (provided by Dr. M. Levine, University of Maryland), and was inserted in
frame between the CTA leader sequence and the CTA2 gene. The resultant plant
expression vector was designated pPCV701CFA/I-CT-NSP4 and contains the CTA2CFA/I fusion gene driven by the mas PI promoter and the CTBh-NSP4 fusion gene
driven by the mas P2 promoter.

b. Plant Transformation
Plant expression vectors pPCV701-CTB, pPCV701CTB-NSP4 and pPCV701
CFA/I-CT-NSP4 were introduced into Agrobacterium tumefaciens strain GV3101
pMP90RK by electroporation [17]. Potato Solanum tuberosum cv. Bintje leaf explants
were transformed with A. tumefaciens harboring the plant expression vectors and
transgenic potato plants were regenerated as described [18].
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c. Analysis of DNA/RNA from Transformed Potato
Plant genomic DNA was isolated from transformed potato leaf tissues using a
DNeasy Plant Mini Kit (Qiagen Inc). Presence of the CTB, NSP4 and CFA/I genes were
determined by PCR analysis using transformed plant genomic DNA (500ng) as a
template and primers specific for each gene. The PCR products were separated by
electrophoresis on a 1% agarose gel stained with ethidium bromide to visualize the bands.
Total RNA from transformed plant leaves was isolated using an RNeasy Plant Mini kit
(Qiagen Inc.). The presence of CFA/I mRNA was determined by RT-PCR analysis
following the instructions included in the Omniscript Reverse Transcriptase kit (Qiagen
Inc.). The RT-PCR samples were separated by electrophoresis on a 1% agarose gel and
stained with ethidium bromide.

d. Immunoblot Analysis of Protein from Transformed Potato
Approximately 1.0 g of leaf tissue was homogenized on ice in 1ml of extraction
buffer (200mM Tris-HCl, pH 8.0, 100 mMNaCl, 400mM sucrose, 10 mM EDTA, 14 mM
2-mercaptoethanol, ImM phenyl-methylsulfonyl fluoride, 0.05% Tween-20). The tissue
homogenates were centrifuged twice at 17,000 x g for 15min at 4° C to remove insoluble
debris. A 10-20 ul aliquot of supernatant fluid containing 100-200 p,g of total soluble
protein determined by protein assay (Bio-Rad Inc.), was analyzed by 12% SDS-PAGE.
Plant homogenate samples were either boiled 5 minutes prior to electrophoresis or loaded
directly on the gel. The expression of CTB, NSP4 and CFA/I protein were detected by
rabbit anti-CTB antiserum (Sigmal:5000 dilution), rabbit anti-NSP4(l 14-135) antiserum
(provided by M. Estes, Baylor College of Medicine, at a dilution 1:1000) or rabbit anti
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CFA/I antiserum (1:1000 dilution). The second antibody used for band detection was an
alkaline phosphatase-conjugated mouse antirabbit IgG (Sigma, at 1:10,000 dilution).

e. Quantification of CTB-NSP4, CFA/I-CTA2 Proteins’ levels in Transformed
Potato
The amount of plant-synthesized CTB-NSP4 fusion protein was measured in
transformed plant extracts by chemiluminescent Gmi ELISA assay [17]. Briefly, the wells
of a 96-well microtiter plate (Dynatech Laboratories) were coated with lOOul/well of
monosialoganglioside Gmi (3.0ug/ml) (Sigma) in pH9.6 bicarbonate buffer (15mM
Na2CG3, 35mM NaHCCb), and incubated at 4° C overnight. The plate was washed three
times with PBST (phosphate buffered saline (PBS) containing 0.05% Tween-20). The
background was blocked by incubation in 1% bovine serum albumin (BSA) in PBS
(300ul/well) at 37° C for 2h followed by washing three times with PBST. The microtiter
plate was incubated with 2ug of transformed plant total soluble protein per well in PBS
(lOOul/well). For use as a positive control, a known amount of bacterial CTB (Sigma)
plus 2ug untransformed plant total soluble protein in PBS (lOOul/well) was added to the
plate and incubated overnight at 4° C. The plate was washed three times with TBST and
then incubated in a 1:8000 dilution of rabbit anti-cholera toxin antibody (Sigma,
lOOul/well) for 2h at 37° C, followed by washing three times with PBST. The plate was
incubated with a 1:80,000 dilution of anti-rabbit IgG alkaline phosphatase conjugate
(Sigma, lOOul/well) for 2h at 37° C and washed three times with PBST. The plate was
finally incubated with lOOul/well Lumi-Phos Plus substrate (Lumigen) for 30 min at 37°
C. The plate was cooled for 5 min and light emission was measured in a Dynatech 3000
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Microtiter Plate Luminometer (Dynatech Laboratories). The amount of plant-synthesized
CFA/I-CTA2 fusion protein in each well was measured by the same chemiluminescent
ELISA assay with the exception that 2ug of transformed plant total soluble protein was
directly coated on the plate in pH9.6 bicarbonate buffer. The first antibody used was
rabbit anti-CFA/I at a 1:3000 dilution. The rest of the assay procedure was identical to the
ELISA described above.

f. Detection of CFA/I-CTA2 and CTB-NSP4 Assembly in Plant Tissues
The assembly of CFA/I-CTA2 subunit with the CTB-NSP4 pentamer in transformed
plant tissues was detected by the chemiluminescent Gmi ELISA assay procedure. The
analysis procedures were the same as for the Gmi ELISA for quantification of CTB-NSP4
fusion protein with the exception that the first antibody used was rabbit anti-CFA/I at a
1:3000 dilution.

3. Results and Discussion
a. Construction of Plant Expression Vectors
The plant expression vector pPCVVOl CFA/I-CT-NSP4 (Figure 1.) was generated by
inserting the CTB-NSP4 gene following the mas P2 promoter and inserting the CFA/ICTA2 gene 3’ adjacent to the mas PI promoter. The mas P1,P2 promoter is a
bidirectional promoter capable of simultaneous expression of two genes in opposite
directions. A glycine-proline hinge region (GPGP), was added separating the CTB
peptide and the NSP4 epitope to increase the flexibility of the fusion peptide. The CTA2
gene was fused to the 5’ end of the CFA/I gene as a linker to facilitate association of the
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CFA/I-CTA2 fusion peptide with CTB pentamer structure. Each fusion gene retains its
bacterial leader sequence and an endoplasmic retention (ER) retention signal at the 3 ’
end. For use as controls, plant expression vectors containing CTB or CTB-NSP4 fusion
genes under control of the mas P2 promoter were included in the transformation
experiments. Fifteen kanamycin resistant transgenic potato plants were regenerated
following A. tumefaciens meditated transformation of potato leaf explants.

b. DNA/RNA Analysis of Transformed Plants
The transformed potato plants were analyzed by PCR for the presence of the CTBNSP4 and the CFA/I-CTA2 gene fusions (Figure 2.). A 560 bp DNA fragment which
included both the CTB and the NSP4 DNA sequences was amplified from the
transformed potato genomic DNA. No nonspecific amplification was observed in
untransformed plant samples, indicating the high specificity of the 5’CTB and the
3’NSP4 primers. Using primers including a 5’ flanking sequence of the CFA/I gene and a
3’ flanking sequence of the CTA2 gene, we detected amplification of a single 590bp
DNA fragment, which is the correct size for the CFA/I-CTA2 fusion gene. Since the PI
promoter is often considered to be 5 to 10 times weaker than P2 promoter, we chose to
study the mRNA transcription of CFA/I gene at the PI side of the mas promoter. Both 5’
and 3’ CFA/I primers were used in the RT-PCR assay. A single 430 bp mRNA fragment
was detected, which is the exact size of CFA/I cDNA. Samples without incubation with
reverse transcriptase showed no band, which indicated that no DNA contamination was
present in the total RNA sample.
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c. Detection of Foreign Proteins in Transformed Plants
The presence of the CTB gene product was identified by immunoblot analysis using
antiserum against cholera toxin (Figure 3A.). Bacterial CTB formed a 45 kD pentamer
structure which was partially dissociated into 11 kD monomers. SDS-PAGE gel
electrophoresis results indicated that the plant derived CTB pentamers were
approximately 50 kD, higher in molecular weight than the bacterial CTB. The
approximately 5 kD molecular mass increase can be attributed to the presence of the
additional SEKDEL sequence and the retention of the bacterial CTB leader sequence.
The plant derived CTB-NSP4 fusion protein also formed an oligomeric structure about
the same size as the plant derived CTB pentamer. Immuno-stained electrophoretically
separated extracts of transgenic plants containing the CFA/I-CTA2 and CTB-NSP4 genes
displayed a 70 kD band, which was significantly higher in molecular weight than the
plant synthesized CTB-NSP4 pentamer. The additional increase in molecular mass can be
attributed to the presence of CFA/I-CTA2 fusion protein. Heat treatment resulted in
dissociation of the multimeric structures into monomers. Plant derived CTB-NSP4 fusion
protein dissociated into a 18 kD monomer. Based on preservation of it’s pentamer or
oligomeric structure in transformed plant extracts, the CTB-NSP4 fusion protein appears
to have retained the conformation required for maintenance of its carrier function. The
bacterial colonization factor CFA/I is made up of 6000 copies of a 20 kD monomer. A
multimer ladder of bacterial CFA/I was detected after SDS-PAGE (Figure 3B, lane 1).
Anti-CFA/I antiserum was found to react with the same 70 kD band detected by anti-CT
antiserum from the plant transformed with the CFA/I-CTA2:CTB-NSP4 fusion genes.
Protein extracts of control plants, transformed only with the CTB-NSP4 gene did not
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cross react with anti-CFA/I antiserum (Figure 3B lanes 5 and 6). The cholera toxin A2
subunit is inserted into the central pore of the B pentamer as a continuous helix.
Hydrophobic interactions between amino acids of the A2 and B subunits contributes to
stabilization of the B pentamer structure. The presence of CFA/I-CTA2 peptide appears
to have made the pentamer more resistant to heat degradation (Figure 3B, lanes 3 and 4).
Immunoblot analysis using antiserum against the NSP4 peptide detected the NSP4
moiety of the CTB-NSP4 fusion protein in monomer form. The reaction was specific and
did not cross react with plant derived CTB protein. The inability to detect the small
NSP4 22 amino acid moiety in its CTB-NSP4 multimeric form on immunoblots may be
due to inclusion of the small NSP4 peptide within the CTB pentameric structure.

d. Quantitation of Protein Levels
The CTB-NSP4 fusion protein expression levels in transformed potato leaf and tuber
tissues were determined by quantitative chemiluminescent ELISA. The amount of plant
CTB-NSP4 protein was measured in comparison with relative light units (RLU) emitted
from a known amount of bacterial CTB protein (Figure 4.). The amount of CTB-NSP4
detected in transformed potato tissues was expressed as a percentage of the total soluble
plant protein (TSP) measured in tuber samples. Plant #15 was found to have the highest
expression level equivalent to approximately 0.01% of TSP and is roughly equivalent to
5-10ug of CTB-NSP4 protein in 3.0g of transgenic potato tuber tissues. Plant #3 was
found to have the lowest CTB-NSP4 expression level of approximately 0.001% of TSP.
Five minutes immersion in boiling water dissociated the CTB multimers into monomers.
However, we were unable to detect light emission from CTB monomers in the boiled
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samples. The expression levels of CFA/I-CTA2 fusion protein ranged from 0.0003% to
0.002% of TSP in transformed plants (Figure 5.). The maximum expression level of
CFA/I-CTA2 fusion protein (0.002% TSP) from the PI mas promoter is 5 times lower
than that of the CTB-NSP4 fusion protein (0.01%) obtained from the mas P2 promoter.

e. Assembly of Subunit Foreign Proteins
Association of the CFA/I-CTA2 fusion protein with the CTB-NSP4 pentamer was
further demonstrated by results obtained from the Gmi ELISA using anti-CFA/I antibody
as the primary antibody. Transgenic plants #1 and #2 transformed with CTB and CTBNSP4 genes respectively were used as control plants. Transformed plants #3 through #7
contained the CFA/I-CTA2:CTB:NSP4 genes (Figure 6.A). Statistical analysis using the
Student’s t-test revealed significant differences among the control plants and the CFA/ICTA2 transformed plants (p<0.05). When the amount of total soluble protein was
increased from 20 pg to 60 pg, the RLU signal emitted from the CTB-NSP4 control plant
remained unchanged at the background level (Figure 6.B). However, in comparison with
the control plants, extracts from the plant transformed with CFA/I showed an increase in
slope proportional with increased tissue amounts that was statistically significant above
the control plant tissues (p<0.05). In Figure 6, panel C, CFA/I peptide was detected in
samples from transformed plants containing the CFA/I-CTA2:CTB:NSP4 genes (Figure
6.C, #1). Boiling dessociated the CTB-NSP4 pentamer. The CFA/I-CTA2 protein was no
longer able to associate with the CTB-NSP4 protein (Figure 6.C, #2). Addition of
purified CFA/I protein to the transformed plant samples containing CTB-NSP4 protein
did not show any positive CFA/I signal indicating that CFA/I protein did not bind
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unspecifically with CTB-NSP4 multimers unless the CTA2 peptide was linked (Figure
6.C, #3 and #4). The CFA/I singals were not detected in untransformed plant
homogenates with the addition of purified CFA/I and NSP4 proteins indicating no
unspecific binding of CFA/I or NSP4 protein with Gmi ganglioside (Figure 6.C, #5 and
#6).
The mas dual promoters are stimulated by the plant hormone indole acetic acid
[19]. Following auxin induction, the expression levels are equivalent to or greater than
constitutively expressed promoters such as the cauliflower mosaic virus 35S promoter
[6,8], the patatin promoter [20]. The bidirectional nature of the mas promoters permit
simultaneous expression of two foreign genes. This advantage may be a benefit for the
production of multi-subunit proteins in plants. Coordinate expression levels between the
mas PI and P2 promoters provide options for the production of different amounts of
subunits, which may in turn, achieve optimal ratios for subunit association. Assembly of
the CFA/I-CTA2 peptide with the CTB-NSP4 pentamer to form a multimeric structure in
plants, similar to the natural form of cholera toxin demonstrates the utility of the mas dual
promoters for expression of multiple subunits of the cholera toxin. Assembly of the
cholera toxin subunits in edible plant tissues provides us with the opportunity to generate
fusion proteins with the cholera subunit peptides. Thus, the cholera toxin-like
multisubunit molecules can be used as an enterocyte targeted carrier molecules to
transport multiple antigens to the surface of the mucosal immune system. The expression
of three antigens CFA/I, CTB, NSP4 from different infectious diseases in one transgenic
plant opens the way for development of multi-component oral vaccines in edible plants.
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Figure 1. Plant expression vectors. Construct (3), pPCV701CFA/I-CT-NSP4 contains all Four genes located within the
transferred DNA (T-DNA) sequence flanked by the right and left border (RB and LB), 25 bp direct repeats required for
integration of the T-DNA into plant genome: 1) CTBH:NSP4:SEKDEL fusion gene is driven by the mas P2 promoter; 2)
CFA/ECTA2 fusion gene is driven by the mas PI promoter; 3) The neomycin phosphotransferase (NPT II) expression cassette
provides resistance to kanamycin for selection of transformed plants; 4) Bla, the (3-lactamase cassette generates resistance to
ampicillin in E.coli and carbenicillin in A.tumefaciens. g7pA, g4pA and OcspA are polyadenylation signals from A.tumefaciens
Tl-DNA gene 7, gene 4 and the octopine synthase gene respectively; Pnos is the promoter of the nopaline synthase gene; Ori
pBR is the replication origin of pBR322 for maintenance of the plasmid in E.coli. Construct (2), pPCV701CTB-NSP4 which has
only CTBH:NSP4:SEKDEL under control of the mas P2 promoter, and construct (1), pPCV701CTB which has only
CTB:SEKDEL under control of the mas P2 promoter, were included as controls.
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Figure 2. DNA/RNA analysis of transformed potato. Panel A. PCR detection of CFA/I-CTA2 cDNA in potato genomic
DNA: Lane 1, 1 kb molecular weight marker; Lane 2, genomic DNA from untransformed potato leaf tissues; Lanes 3 through 5,
genomic DNA from leaf tissues of potato plants transformed with plant expression vector pPCV701CFA-CT-NSP4. Panel B.
PCR detection of CTBH-NSP4 cDNA in potato genomic DNA: Lane 1, 1 kb molecular weight marker; Lanes 2 through 5,
genomic DNA from leaf tissues of potato plants transformed with plant expression vector pPCV701CFA-CT-NSP4; Lane 6,
genomic DNA from untransformed potato plant leaf tissues. Panel C. RT-PCR detection of CFA/I mRNA: Lane 1, 100 bp
molecular weight marker; Lanes 2 and 3, total RNA preparations from untransformed potato leaf tissues; Lanes 4 through 7,
total RNA preparations from potato leaf tissues transformed with plant expression vector pPCV701 CFA-CT-NSP4; Lanes 4
and 6, PCR reaction without reverse transcriptase.
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Figure 3. Immunoblot detection of CTB-NSP4 and CFA/I-CTA2 fusion proteins in transformed potato tuber tissues.
Panel A. Immunoblot with anti-CT antiserum: Lane 1, molecular weight markers; Lanes 2 through 5, unboiled samples; Lanes 6
through 9, boiled potato samples; Lanes 2 and 6, 100 ng bacterial CTB; Lanes 3 and 7, 100 pg total soluble protein from potato
plants transformed with the CTB gene; Lanes 4 and 8, lOOug total soluble protein from potato plants transformed with the CTBNSP4 fusion gene; Lanes 5 and 9, 100 pg total soluble protein from potato plant transformed with CFA/I-CTA2 and CTB-NSP4
fusion genes. Panel B. Immunoblot with anti-CFA/I antiserum. Lane 1, molecular weight markers; lane 2, 100 ng boiled
bacterial CFA/I protein; Lanes 3 and 4, unboiled and boiled 200 pg total soluble protein from potato plants transformed with
CFA/I-CTA2:CTB-NSP4 double fusion genes; Lane 5, unboiled and Lane 6, boiled potato tuber tissues containing the CTBNSP4 gene (200 pg total soluble protein each lane). Panel C. Immunoblot using anti-NSP4 antiserum as the primary antibody.
Lanes 1 through 3, unboiled tuber tissue samples; lanes 4 through 6, boiled tuber tissue samples. Lanes 1 and 4, 200 pg total
soluble protein from potato tubers transformed with the CTB gene; lanes 2 and 5, 200 pg total soluble protein from potato plants
transformed with the CTB-NSP4 fusion gene; lanes 3 and 6, 200 pg total soluble protein from potato plants transformed with the
CFA/I-CTA2:CTB-NSP4 fusion genes.
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Figure 4. Quantitation of CTB-NSP4 fusion protein levels in transformed potato tissues. Anti-CT antiserum was used as
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transformed potato plants #3 and #15 were either boiled or directly used for GM1 ELISA assay. An untransformed plant was
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Figure 6. Detection of CFA/I-CTA2 and CTB-NSP4 fusion protein assembly in
transformed potato plants. Panel A. A chemiluminescent GM1 ELISA was performed
with plant homogenates containing 20 pg of total soluble protein (TSP). Rabbit antiCFA/I antiserum was used as the primary antibody. Sample #1 is an extract of a control
plant transformed with the CTB gene only. Sample #2 is an extract from a control plant
transformed with only the CTB-NSP4 gene. Samples #3 through #7 are extracts from
plants transformed with the CFA/I-CTA2:CTB-NSP4 fusion protein genes. Panel B.
Presents a chemiluminescent GM1 ELISA performed with increasing amounts of total
soluble protein from transformed plant tissues. Rabbit anti-CFA/I antiserum was used as
the primary antibody. Line #1 represents the RLU values obtained from a control plant
transformed with the CTB-NSP4 gene only. Line #2 represents the RLU values obtained
from a plant transformed with the CFA/I-CTA2:CTB-NSP4 fusion genes. Panel C. A
chemiluminescent GM1 ELISA was performed with plant homogenates mixed with
purifed CFA/I or NSP4 proteins. Rabbit anti-CFA/I antiserum was used as the primary
antibody. Sample #1 and #2 are unboiled and boiled extracts from plants transformed
with both CFA/I-CTA2 and CTB-NSP4 fusion genes respectively. Sample #3 and #4 are
unboiled and boiled extracts from plants transformed with the CTB-NSP4 fusion gene
mixed with 200 ng purified CFA/I protein. Sample #5 is untransformed plant homogenate
mixed with 200 ng purified CFA/I. Sample #6 is untransformed plant homogenate mixed
with 200 ng purifed NSP4 proteins.
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Abstract

To generate a plant based multicomponent oral vaccine against cholera, rotavirus and
enterotoxigenic E.coli (ETEC), we have constructed transgenic potato plants that
synthesize the cholera toxin B and A2 subunits, the rotavirus enterotoxin NSP4 22 amino
acid epitope and the ETEC fimbrial antigen CFA/I. To facilitate delivery of the plant
synthesized antigens to the gut-associated lymphoid tissues, the rotavirus NSP4 epitope
was linked to the cholera toxin B subunit (CTB) and the ETEC fimbrial antigen CFA/I
was linked to the cholera toxin A2 subunit. The cholera toxin fusion proteins expressed in
transformed potato tuber tissues assembled into a cholera holo-toxin-like oligomeric
structure, which retained enterocyte membrane receptor GMi-ganglioside binding affinity.
Both serum and intestinal antibodies against NSP4, CFA/I and CTB were induced in
orally immunized mice. Analysis of IL-2, IL-4 and INFy cytokine levels in spleen cells
isolated from immunized mice indicated the presence of a strong Thl immune response
to the plant synthesized antigens. Fluorescent antibody based flow cytometry analysis of
immunized mouse spleen cells showed an increase in CD4+ but not CD8+ memory cell
populations. Following rotavirus challenge, passively immunized mouse pups showed a
50% reduction of diarrhea symptoms. The experimental results indicate that food plants
can serve as vehicles for production and distribution of multiple antigens for
simultaneous immunization against several enteric diseases.
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1. Introduction.
Acute gastroenteritis is second only to acute respiratory disease as a cause of death
worldwide (Kiyono, et ah, 1996). Cholera, rotavirus and ETEC are the three major
causative agents of acute infectious enteric diseases. Recently, the successful utilization
of plants as production and delivery systems for pathogen antigens has been reported
(Mason et al.,1992, 1996; Arakawa et al., 1997; Modelska et al., 1998) The plant
expressed antigens were able to generate protective antibodies in orally immunized
animals (Thanavala et al., 1995; Haq et al., 1995; Arakawa et al., 1998). However the
relatively low expression levels of foreign antigens synthesized in transgenic plants
coupled with the modest immune response following oral immunization remain limiting
factors for development of an effective plant-based vaccine. The recent expression and
successful assembly of cholera toxin B subunits into biologically active oligomeric
structures in transgenic potato plants (Arakawa et al., 1997) provides a valuable approach
for targeting plant synthesized antigens to the gut associated lymphoid tissues (GALT).
Cholera toxin possesses distinct carrier and adjuvant properties. Antigens genetically
fused to cholera toxin A or B subunit were found to stimulate strong immune response in
orally immunized animals (Czerkinsky et al., 1989; Holmgren et al., 1993). In this report,
we have expressed a cholera toxin fusion with two different disease antigens in
transformed potatoes. In a C-terminal fusion, we linked the twenty two amino acid
immunodominant epitope of the murine rotavirus enterotoxin NSP4 to the cholera toxin
B subunit (CTB), and in a N-terminal fusion we fused the ETEC fimbrial colonization
factor CFA/I to the cholera toxin A2 subunit (CTA2). Following A.tumefaciens
transformation of potato leaf tissue with a plant expression vector carrying the two
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cholera toxin fusion protein genes we regenerated transformed plants. Female CD-I mice
were immunized by feeding transformed potato tuber tissues containing the cholera toxin
fusion proteins. The titers of serum IgG and intestinal IgG and IgA antibodies against
NSP4, CTB and CFA/I were measured in the immunized mice. Spleen cells from
immunized mice were analyzed for IL-2, IL-4 and IFNy cytokine secretion and T
lymphocyte subpopulations. Passively immunized mouse pups from orally immunized
dams were challenged with SA-11 rotavirus to determine the level of protection against
rotavirus IFNection delivered by the plant-based vaccine.

2. Experimental Protocol
a. Plant Expression Vector Construction and Plant Transformation
The plant expression vector pPCV701CFA/I-CTB-NSP4 was assembled from the
parental plasmid pPCVTOl in the following manner. A nucleotide sequence encoding the
endoplasmic reticulum (ER) retention signal, SEKDEL was first cloned into the plant
expression vector pPCVVOlon the P2 site of the mannopine synthase {mas) dual PI, P2
promoter. The CTB gene and its leader sequence were amplified by polymerase chain
reaction (PCR) from the cholera toxin (ctxAB) operon in plasmid pPT42 (provided by J.
Mekalanos, Harvard University, Medical School). The CTB 3’ primer was designed to
contain an oligonucleotide encoding the tetrapeptide hinge (Gly-Pro-Gly-Pro) to
incorporate a degree of flexibility between the CTB and NSP4 peptides. A synthesized
DNA fragment encoding the rotavirus enterotoxin NSP4 (114-135) epitope was inserted
in frame between the CTB-hinge and the SEKDEL sequences. The CTA leader sequence
and the CTA2 gene were amplified by PCR from the ctxAB operon and cloned into
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pPCvTOl downstream of the mas PI promoter region. A DNA fragment encoding the
ETEC colonization factor CFA/I (431bp) was amplified from plasmid pIGxlSA
(provided by Dr. M. Levine, University of Maryland), and was inserted in frame between
the CTA leader sequence and the CTA2 gene. The resultant plant expression vector
pPCV701CFA/I-CTB-NSP4 was introduced into Agrobacterium tumefaciens strain
GV3101 pMP90RK. From sterile plants grown in culture medium in a light room, potato
{Solarium tuberosum cv. Bintje) leaf tissue explants were transformed with A
tumefaciens harboring the plant expression vector pPCV701 CFA/I-CTB-NSP4.
Transformed plants were regenerated from the explants on selection medium containing
kanamycin. Prior to analysis of antigen gene expression transgenic tubers were stimulated
to produce high levels of the antigen proteins by incubation of tuber slices on growth
medium containing auxin 2,4-D (2,4 dichlorophenoxy acetic acid) for 4 days at room
temperature.

b. Immunoblot Detection of the CFA/I and CTB-NSP4 Fusion Proteins
Protein extracts from auxin stimulated transformed potato tubers containing 100 pg of
total soluble protein (TSP) were loaded on a 10-15% SDS-PAGE gel with or without 5
min boiling prior to electrophoresis. The separated protein bands were transferred to
nitrocellulose membrane by electroblotting on a semi-dry blotter (Sigma) at 30V, 60mA
for one and a half hours. The location of CTB, NSP4 and CFA/I proteins were identified
by incubation of the blot in rabbit anti-CTB antiserum (Sigma 1:5000 dilution) overnight
at room temperature followed by incubation in alkaline phosphatase-conjugated mouse
anti-rabbit IgG (Sigma, at 1:10,000 dilution) for 2 hours at room temperature. Finally the
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membrane was incubated in the substrate BCIP/NPT (Sigma) for lOmin. The color
reaction was stopped by washing the membrane several times in distilled water.

c. Mouse Immunization and Cell Cultures
A group of 10 CD-I female mice each were fed 3g trangenic potato tuber tissues
containing a total of 7 pg of the recombinant fusion proteins previously determined by
chemiluminescent ELISA on day 0, 5, 15, 23 and 56. Using the same feeding schedule, a
group of 5 CD-I mice each were fed 3g of untransformed potato tuber tissues as a
negative control. To evaluate the adjuvant effect of the CTB protein in the CTB-NSP4
fusion, CD1 mice (5 per group) were gavaged with pure NSP4 peptide with or without
pure bacterial CTB (adjuvant) according to the same oral inoculation schedule. On day 13
after the final immunization, blood was taken from each mouse for serum antibody titer
determination. Three mice per group were euthanized at three different time points: 13,
34 and 68 days after the fifth immunization. Intestinal washing were collected for
mucosal antibody detection. Spleen cells from both immunized and negative control mice
(3x 106 cells/well) were suspended in RPMI 1640 medium containing 10% fetal calf
serum in duplicate samples, in 24 well tissue culture plates. After incubation for 72 h at
37° C in a humidified, 5% CO2 incubator, supernatants from the spleen cell cultures were
collected for assessment of IL-2, IL-4 and IFNy secretion.
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d. Cytokine and Flow Cytometric Analysis of T Lymphocyte Populations in
Immunized Mice
IL-2, IL-4 and IFNy produced in the spleen cell culture supernatants were assayed by
ELISA (kits supplied by Endogen, Inc.). Spleen lymphocytes were stained with
fluorochrome-labeled monoclonal antibodies (mAh) for immunophenotyping. Two
monoclonal antibody panels were constructed for three color analysis
(fluoresceinisothiocanate (FITC), phycoerythrin (PE), and Cy-Chrome). The first
combination used, CD62L*FITC/CD4*PE/CD44*Cy-Chrome designates naive and
memory T helper cells. The second combination, CD62L*FITC/CD8b.2*PE/CD44*CyChrome designates naive and memory cytotoxic T cells. The spleen cells were
resuspended at 106 cells/ml in PBS and stained with fluorochrome-labeled mAbs. The
labeled cells were analyzed by flow cytometry to determine the T lymphocyte memory
cell sub-populations.

e. Evaluation of Protection against Rotavirus Challenge
Adult female CD-I mice (five per group) were fed 3 g of untransformed or trangenic
potato tuber slices once a week for four weeks. Immediately following the fourth
immunization at maximum anti-NSP4 antibody titer, the mice were mated with
uninfected males. After a 19-20 day gestation period, mouse pups were bom to the
immunized dams. On day 6 post parturition, each pup received one oral dose of simian
rotavims SA-11 in 50 pi PBS that contained 15 DD5o (the vims dose determined
empirically to cause diarrhea in 50% of the mouse pups). The mice were examined for
the presence of diarrhea daily for 5 days following inoculation by gentle palpation of
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their abdomen to produce fecal pellets. The diarrhea score and the proportion of mice
showing diarrhea symptoms in each study group were recorded.

3. Results and Discussion
a. Expression of CFA/I-CTA2 and CTB-NSP4 Fusion Genes
The CTB-NSP4 fusion gene was cloned into plant expression vector pPCV701 under
control of the mas P2 promoter. The CFA/I-CTA2 fusion gene was cloned downstream of
mas PI promoter. Each cholera toxin fusion gene contains its own leader sequence and an
ER retention signal. To increase the flexibility of the fusion protein, a four amino acid
glycine -proline (GPGP) hinge region was inserted between the CTB and NSP4 peptides
(Figure 1). Transformed potato plants were generated from leaf explants following an A
tumefaciens meditated stable transformation method (Arakawa et ah, 1997).
Bacterial CTB (Figure 2, panel A, lanel) assembled into an oligomeric structure
with a molecular weight of 45 kD, characteristic of the CTB pentamer. Plant produced
CTB-NSP4 fusion peptide (Figure 2, panel A, lane2) formed a 50 kD oligomeric
structure. The 5 kD increase in molecular mass is consistent with the presence of the
additional NSP4 peptide and the 6 amino acid SEKDEL signal. The plant sample
containing both CFA/I-CTA2 and CTB-NSP4 fusion proteins (Figure 2, panel A, lane3)
showed the presence of a 70 kD protein band, indicative of the insertion of CFA/I-CTA2
peptide into the CTB-NSP4 pentamer. The untransformed plant (Figure 2, panel A, lane
4) showed no cross reaction with the cholera toxin antibody. Immersion of the samples in
boiling water for 5 min resulted in dissociation of the multimeric structures into
monomers (Figure2, panel B). The bacterial CTB monomer has a molecular mass of 11
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kD. The plant derived CTB-NSP4 multimer dissociated into an 18 kD monomer which is
the consistent with the molecular mass of CTB plus NSP4.

b. Induction of Serum and Intestinal Antibodies in Orally Immunized Mice
Following five oral inoculations with transgenic potato tuber tissues, blood samples
were collected and the serum anti CTB, NSP4 and CFA/I IgG titers were measured by
ELISA methods. Out of 10 mice, 8 generated serum IgG against CTB with a mean titer of
312.5±81.3. Of thelO immunized mice, 8 developed serum IgG against NSP4 with a
mean titer of 125±61.23. Out of the 10 immunized mice, 10 developed serum IgG against
CFA/I with a mean titer of 84± 44.2 (Figure 3, panel A).
Intestinal IgG and IgA antibody titers against the three antigens were analyzed by a
chemiluminescent ELISA method. Out of 10 immunized mice, 5 generated measurable
intestinal anti CTB antibody titers; Out of 10 immunized mice, 5 were found to have
measurable intestinal antiNSP4 antibody titers and 6 out of 10 mice were found to have
significant intestinal anti CFA/I antibody titers (Figure 3, panel B). The intestinal
antibody titers were relatively low in comparison with serum IgG levels. Negative control
mice fed untransformed potato tuber tissues did not develop detectable specific serum or
mucosal antibodies (Figure 3, panel A, B). The induction of both systemic and mucosal
antibodies in the immunized mice indicated the successful delivery of the cholera toxin
fusion proteins to the GALT.
Adjuvant and carrier functions of CTB in the CTB-NSP4 fusion protein were
determined by measuring serum anti-NSP4 antibody titers in mice from different
vaccination groups. Mice fed the NSP4 peptide alone generated the lowest anti-NSP4
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titer. Immunization with 7 fag of bacterial CTB (the same amount detected in the plant
derived CTB-NSP4 fusion protein) increased the serum anti-NSP4 IgG titer
approximately two folds. Mice fed 3 g transformed potato tuber tissues containing the
CTB-NSP4 fusion protein developed the highest anti-NSP4 titer (Figure 4). Small soluble
proteins like the NSP4 22 amino acid epitope that are highly imunogenic by parenteral
routes are frequently ineffective when administered orally unless a large dose of the
protein is used (Bloom et ah, 1996; Cox et ah, 1984). This result can be attributed to
intestinal digestion and lack of tropism of the peptide for the gut associated lymphoid
tissues. Either cholera holotoxin or the CTB subunit, which function as mucosal
adjuvants can stimulate an immune response against co-administered protein antigens
(Lycke et ah, 1986; Mckenizie and Halsey, 1984; Sun et ah, 1994; Jackson et ah,1993).
Directly linking small antigens with CTB subunit not only results in specific targeting of
the antigens to the mucosal immune system via specific enterocyte attachment but also
increases the local antigen concentration at the mucosal surface, which may explain our
detection of the strongest immune response directed against the CTB-NSP4 fusion
protein.

c. Cytokine Assays and Detection of CD4 Memory Cells
Following multiple oral immunizations, the IL-2 and the IFNy expression levels in
spleen cells dramatically increased, reaching the highest level 34 days after the fifth
immunization and decreasing to basal levels by 68 days after vaccination. Throughout
this time period IL-4 levels remained low, equivalent to that found in unimmunized mice
(Figure 5). Thus, cytokine expression pattern clearly indicated a Thl lymphocyte
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mediated immune response generated by feeding mice the plant derived cholera toxin
fusion antigens. Both cholera toxin and the CTB subunit function as potent adjuvants that
can promote antigen priming of both Thl and Th2 type of CD4+ T precursor cells
(Marinaro et ah, 1999; Williams et ah, 1999). The pattern of the T helper lymphocyte
response may depend on the nature of the co-administered antigens (Xu-Amano et ah,
1994). Oral immunization with CTB-insulin or CTB-GAD fusion proteins generate a Th2
response while oral immunization with recombinant E.coli CFA/I stimulated a biphasic
Th response; a predominant Th2 response at the early stage and then Thl cell dominant
response 4 weeks after immunization (Arakawa et ah, 1998; Pascual et al.,1999). The
rotavirus non-structural protein NSP4, which acts as a viral enterotoxin, stimulated
increased production of IL-2 and IFNy in humans (Ball et ah, 1994). Therefore we were
not surprised to see the overall cytokine secretion pattern of this multicomponent plant
vaccine in the mouse model to be indicative of a strong Thl response. Flow cytometry
analysis of spleen cells collected on day 13, 34 and 68 after the last vaccination showed
an elevated population of CD4+ memory cells in comparison with the unimmunized mice
through the two months after immunization (Figure 6, panel C). The distribution of CD4
T cell subsets is shown in Figure 6. The CD4+ memory cell subpopulation (CD62‘
CD44+, gate R4) detected in the immunized mice (panel A) was observed to be
significantly higher than the CD4+ memory cell subset in unimmunized mice (panel B).
Thus, the generation of a significantly increased T helper memory cell population in the
immunized mice indicated successful protective immunization mediated by the plant
delivered antigens. The existence of increased numbers of memory cells provided the
ability to mount a strong immune response following a second encounter with the same
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pathogen. The CD8+ memory cell population detected in immunized mice did not show
any significant increase over the unimmunized mouse negative control group (data not
shown). This result may be explained by the temporary weak cytotoxic immune response
often characteristic of oral immunization (Svennerholm et al., 1984; Czerkinsky et ah,
1993).

d. Rotavirus Challenge and Diarrhea Reduction
Anti-NSP4 antibody protection against rotavirus induced diarrhea was evaluated by
virus challenge of pups bom to dams previously immunized with the plant derived CTBNSP4 fusion protein (Horie et al., 1999). The number of pups which developed diarrhea
symptoms and the duration of the diarrhea was significantly reduced in the pups
passively immunized with CTB-NSP4 fusion protein in comparison with pups bom to
unimmunized dams. On day 3 after rotavims challenge a 50% reduction of diarrhea
symptoms was detected in the immunized pups. Complete resolution of diarrhea
symptoms occurred 4 days after vims challenge in pups from immunized dams (Figure 7,
the third column in each group). To exclude the possibility of diarrhea reduction due to
the presence of anti-CTB antibodies, pups bom to dams immunized with plant derived
CTB only were also challenged with an identical dose of rotavims SA11 (Figure 7,
second column in each group). No reduction of diarrhea symptoms was detected in mice
immunized with plant derived CTB alone. This experiment demonstrated that anti-NSP4
antibodies generated in orally immunized mice were passed on to the pups and protected
them from the onset of rotavims infection as well as significantly reducing the duration of
the vims infection.
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e. Development of Plant-based Multicomponent Oral Vaccines
Mucosal vaccines capable of inducing both humoral and mucosal immunity would
provide the most ideal defense against infectious enteric diseases. However most soluble
protein antigens are sensitive to PH and enzymatic digestion in the stomach and intestinal
tract (Kiyono et ah, 1996). However, cholera toxin is a remarkably stable protein and a
potent immungen and has been successfully synthesized in bacterial or viral systems as a
carrier molecule for the transfer of chemically or genetically fused antigens
(Hajishengallis et al., 1995; Dertzbaugh et al., 1990,1993). Initial mucosal immunization
experiments in which synthesis of the CTB subunit in transgenic potato, which was
followed by oral immunization of mice with transformed plant tissues demonstrated a
significant protective effect of the plant-based vaccine and has opened the way for
development of effective mucosal vaccines in stably transformed plants (Arakawa et al.,
1998). Based on this result, cholera toxin fusion proteins with other antigens expressed in
plants became the next logical focus for the development of food plant based oral
vaccines. Thus, the additional finding that the cholera toxin A2 subunit-CFA/I fusion
protein associates with the cholera toxin B subunits to form a holotoxin like oligomer
capable of binding to gangliosides present in the enterocyte membrane now provides us
with the opportunity to generate multicomponent vaccines in plants in which several
antigens can be targeted to the mucosal immune system for greater protection efficacy.
Oral inoculation of GDI mice with the multicomponent plant vaccine induced significant
levels of humoral and mucosal antibodies against CTB, NSP4 and CFA/I antigens.
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Further, the anti-NSP4 antibodies in passively immunized mouse pups offered protection
against rotavirus challenge.
Cholera toxin neutralization assays and mouse ileal loop ligation assays previously
performed in our laboratory on mice immunized with potato synthesized CTB provided a
significant protective effect against diarrhea generated by cholera toxin (Arakawa et ah,
1998). The protective efficacy studies with cholera toxin were not repeated because in
our present animal immunization study the anti-CTB antibody titer detected was 5 fold
higher than obtained in our previous experiments.
T helper lymphocytes play important roles in generating antigen specific humoral
and cell mediated immune responses. Serum and mucosal antibodies can be induced
either through Thl or Th2 cell responses depending on the nature of the antigen peptide
presented to lymphocyte in the lamina propria of the intestinal tract (Xu-Amano et al.,
1998). Cytokine assays performed on spleen cells isolated from immunized mice
indicated the presence of a strong Thl lymphocyte response, possibly including cytolytic
T cells. Detection of a CTL response may be due to the presence of a viral antigen NSP4
in the CTB fusion protein (Angel et al., 1998). The observed Thl response correlated
with the appearance of modest titers of mucosal antibodies. Detection of lymphocyte
populations from immunized mice by flow cytometry analysis showed a stable T helper
memory cell population two months after vaccination. Following immunization the CD8
cell population remained unchanged in the spleen cell flow cytometry analysis. Previous
cell sorting experiments indicate that the cytotoxic T cell response in the spleen may not
be a good indicator of the localized cytotoxic T cell response at the mucosal surface
(Ishida et al., 1997). The expression of multiple antigens in individual transgenic plants
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and the significant antibody titer and protective immune response generated against all
of the antigens by the mammalian mucosal immune system in response to mucosal
immunization with transformed plant tissues opens the way for production of food plant
based vaccines with increased protective efficacy against individual virus or bacterial
pathogens (multivalent vaccine) or multiple pathogens (multicomponent vaccines).
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Figure 1. Plant expression vector pPCVTOl CFA/I-CT-NSP4. Plant expression vector pPCV701CFA/I-CT-NSP4 contains all
four genes located within the transferred DNA (T-DNA) sequence which is flanked by the right and left border (RB and LB),
25bp direct repeats required for integration of the T-DNA sequence into plant genomic DNA. The CTBH:NSP4 (114135):SEKDEL coding sequence is under control of the mas P2 promoter. The CFA/I:CTA2 coding sequence is under control of
the mas PI promoter. The NPT II gene expression cassette was included in the T-DNA to provide resistance to kanamycin for
selection of transformed plants. A (3-lactamase gene cassette was included to provide resistance to ampicillin for selection in
E.coli and carbenicillin for selection in A.tumefaciens. The g7pA polyadenylation signal is from the A.tumefaciens Tl-DNA
gene 7 and the OcspA polyadenylation signal is from the octopine synthase gene.
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Figure 2. Immunoblot detection of CTB-NSP4 and CFA/I-CTA2 fusion proteins in transgenic potato tuber tissues. Panel
A. The oligomeric CTB-NSP4 fusion protein was detected with anti-CT antibody as the primary antibody and anti-mouse IgG
conjugated to alkaline phosphatase as the secondary antibody. Lane 1 = 100 ng commercial bacterial CTB pentamer; Lane 2 =
100 pg total soluble protein (TSP) from potato plants transformed with the CTB-NSP4 fusion gene; Lane 3 = 100 pg TSP from
potato plants transformed with both CTB-NSP4 and CFA/I-CTA2 fusion genes; Lane 4 = 100 pg TSP from an untransformed
potato plant. Panel B. Immunoblot detection of monomeric CTB-NSP4 fusion protein with anti-CT antiserum after boiling the
plant homogenates for 5 minutes in SDS containing buffer. Lanel = 100 ng boiled commercial bacterial CTB monomer; Lane2
= 100 pg boiled TSP from an untransformed potato plant; Lane 3 = 100 pg of boiled TSP from potato plants transformed with
the CTB-NSP4 gene; Lane 4 = 100 pg boiled TSP from potato plants transformed with both CTB-NSP4 and CFA/I-CTA2
genes.
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Figure 3. Measurement of anti- CTB, NSP4 and CFA/I antibody titers in mice after
oral immunization with transgenic potato tuber tissues. CD-I mice were fed
transgenic potato tissues containing 7 pg of CTB-NSP4 and CFA/I-CTA2 fusion proteins
five times at one week intervals. Mice fed equal amounts of untransformed potato tissues
served as a negative control. Panel A. serum IgG antibody titers against CTB, NSP4 and
CFA/I proteins. Panel B. Intestinal IgG and IgA antibody titers against CTB, NSP4 and
CFA/I proteins. Antibody titers were determined by chemiluminescent ELISA method.
The antibody titer was defined as the reciprocal of the highest dilution of the serum or
intestinal contents sample that generated a luminescence signal above the background
levels.
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Figure 4. The adjuvant and carrier functions of CTB in CTB-NSP4 fusion protein. Serum IgG antibody titers against the
NSP4 peptide were measured following mucosal immunization of mice from selected vaccination groups. From left to right
group one was made of mice fed 3g of untransformed potato tuber tissues. Group two was made of mice fed 7 pg of synthetic 22
amino acid NSP4 peptide. Group three consisted of mice fed 7 pg NSP4 synthetic peptide mixed with 7ug of commercial
bacterial CTB. Group four was made of mice fed 3g transgenic potato tuber tissues containing approximately 7 pg CTB-NSP4
fusion protein. Responders: The number of mice which developed a detectable serum IgG titer against NSP4 peptide in each
group divided by the total number mice immunized.
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Figure 5. Measurement of cytokine levels in spleen cells from mice immunized with
potato tissues containing CTB, NSP4 and CFA/I proteins. Spleen cells were isolated
from unimmuized CD-I mice and mice immunized with potato tuber tissues containing
CTB-NSP4 and CFA/I-CTA2 antigens. Supernatants from the spleen cell culture were
assayed for the presence of IL-2, IL-4, and IFNy levels on day 13, 34 and 68 after the
final oral immunization. The levels of IL-2, IFNy and IL-4 were defined as the amount of
the cytokines produced in 1ml spleen cell culture (3 x 106 cells). Grey bars represent the
cytokine levels of unimmunized mice. Black bars represent the cytokine levels of mice
orally immunized with tuber tissues containing CTB-NSP4 and CFA/I-CTA2 antigens.
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Figure 6. Detection of CD4+ memory cells in spleen cells from mice immunized with transgenic potato tissues. Panels A
and B are flow cytometry analysis of CD4+ T cell sub-populations isolated from the spleen of unimmunized CD-I mice and
mice immunized with potato tissues containing CTB-NSP4 and CFA/I-CTA2 fusion proteins. Cells were stained with FITCconjugated anti-CD62 and CYC-conjugated anti-CD44 monoclonal antibodies as described in methods. The cells were
recovered, washed by centrifugation, and analyzed by flow cytometry. The chart scale is logio of the fluorescence intensity.
Panel A represents CD4+ spleen cells from a mouse fed untransformed potato tissues. Panel B, CD4+ spleen cells from a mouse
fed transgenic potato tissues. Panel C is the analysis of CD4+ memory cells in the spleen of immunized mice. Spleen cells were
collected at 13 days, 34 days and 68 days following the last immunization. The first column in each group (gray) represents the
% of memory cells in mice fed untransformed potato tissues. The second column in each group (black) indicates the % of
memory cells in mice fed trangenic potato tissues.
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Abstract
We have expressed the gene encoding rotavirus capsid protein VP6 in transgenic
potato plants. The plant produced VP6 protein has a molecular mass similar to purified
virus VP6 and partially formed VP6 trimers. Mice orally immunized with transformed
potato tuber tissues containing VP6 protein generated significant serum and intestinal
antibody titers against VP6 capsid protein. This work represents the first successful step
in development of an edible plant-based vaccine against rotavirus.
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1. Introduction
Rotaviruses are the leading cause of viral gastroenteritis in young children and
animals worldwide. Rotavirus infection leads to about 870,000 deaths annually in
developing countries (Bishop et ah, 1983). The health burden of rotavirus disease in the
United States is comparable to measles, pertussis and varicella prior to universal use of
vaccines. A cost-effectiveness analysis of a rotavirus immunization program in the U.S.
indicated that a vaccine efficacy rate of 50% could yield net savings of $79 million to
health care and $ 466 million to society (Bajolet et al., 1998).
Rotavirus particles consist of 11 dsDNA genomic segments surrounded by three
concentric capsid protein layers: an inner VP2 layer, an intermediate VP6 layer and an
outer layer made up of capsid proteins VP7 and VP4. TheVP7 capsid protein is a
glycoprotein that defines the G serotype of the rotavirus strain (Mackow et al., 1989).
The capsid protein VP4, a viral hemagglutinin is an important determinant of virulence.
Both VP4 and VP7 induce neutralizing antibodies (Estes, 1996). Serum IgG antibodies
against VP4 and VP7 protect mice against rotavirus infection when administered orally
(Ward et al., 1990; Ishida et al., 1997). The capsid protein VP6 is the major structural
protein of rotavirus, makes up about 50% of virion mass (Hsu et al., 1997). Antibody to
VP6 does not have neutralizing activity in vitro. However, IgA antibodies against VP6
transferred into the intestine via transcytosis (backpack tumor model) protected mice
against virus challenge (John et al., 1996). This result indicates that immunity to internal
proteins may also play a significant role in immunological protection.
Rotavirus capsid proteins produced in insect cells were found to assemble into virus
like particles (VLPs) and induced protective immunity against virus challenge (Corsaro et
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al., 1996; Crawford et al., 1994; Conner et al.,1996). In the present study we have
expressed the rotavirus capsid protein VP6 in transgenic potato plants to demonstrate that
plants can be used as a safe and economical alternative for production and delivery of
recombinant rotavirus proteins for protection against rotavirus infection.

2. Materials and Methods
a. Construction of Plant Expression Vector and Plant Transformation
A 1.2 kbp DNA fragment containing the gene encoding murine rotavirus VP6 was
obtained by BamHI digestion of plasmid pKS+VP6 (kindly provided by Dr. H.B.
Greenberg, Stanford University, School of Medicine) and cloned into plant expression
vector pPCVTOl at the BamHI site under the control of the mas P2 promoter. The
orientation and sequence of the VP6 gene was confirmed by DNA sequence analysis. The
resultant plasmid pPCVTOl VP6 was transferred into A.tumeficiens strain
GV3101pMP90RK by electroporation. The structure of the plasmid in the transformed
GV3101 strain was verified by restriction endonuclease digestion of the plasmid DNA
and analysis of the DNA fragment size and pattern by agarose gel electrophoresis. Potato
(S. tuberosum cv. Bintje) leaf explants were transformed with A.tumefaciens strain
GV3101pMP90RK harboring the plant expression vector pPCV701VP6. Transformed
plants were regenerated from transformed leaf explants grown on MS medium containing
kanamycin (100 pg/ml) for selection of transformants. Prior to analysis of VP6 gene
expression, transformed potato tubers were stimulated to produce maximum levels of
VP6 protein by incubation of tuber slices on solid growth medium containing auxin 2,4-D
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(2,4 dichlorophenoxy acetic acid, 5 mg/1) for 4 days in the growth room at room
temperture.

b. Immunoblot Detection of VP6 Protein
Potato tubers induced by auxin 2,4-D on MS medium were homogenized with a
mortar and a pestle in extraction buffer containing 200 mM Tris-Cl, pH 8.0, 100 mM
NaCl, 400 mM sucrose, 10 mM EDTA, 14 mM 2-mercaptoethanol, 1 mM
phenylmethylsulfonyl fluoride, 0.05% Tween 20. The tissue homogenates were clarified
by centrifugation 2 times at 17,000 x g for 15 minutes at 4° C. The total soluble protein
present in the clear supernatants was determined by Bio-Rad protein assay. Tuber
extracts containing 100 pg total soluble protein were loaded per lane and separated by
SDS/PAGE gel electrophoresis. The separated protein bands were transferred from the
gel to a nitrocellulose membrane by electroblotting on a semi-dry blotter (Sigma) at 30V,
60mA for one and a half hours. The membrane was blocked in 5% dry milk in TBS
buffer (20mM Tris, pH7.5, 500mM NaCl). The membrane was first probed with rabbit
anti-rotavirus serum diluted 1: 500 in 1% dry milk/ TBS buffer and second with alkaline
phosphatase conjugated mouse anti-rabbit IgG(Sigma) at a 1:10,000 dilution in 1% dry
milk/ TBS buffer. Finally the membrane was incubated in the chemiluminescent substrate
BCIP/NBT (Sigma) for 10 minutes. The reaction was stopped by washing the membrane
in distilled water.
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c. Quantification of VP6 Expression Levels by Chemiluminescent ELISA
A 96 well microtiter plate was coated with mouse anti-VP6 serum diluted 1:1,000 in
bicarbonate buffer (pH 9.6) at 4°C overnight. The plate was blocked with 1% BSA in
PBS buffer at 37°C for 2 hours. Protein extracts from transformed potato tuber tissues
were added to the microtiter plate wells and incubated overnight at 4°C. Known amounts
of purified virus VP6 were mixed with protein extracts from untransformed potato tuber
tissues to generate a standard curve. The plate was first incubated with rabbit anti
rotavirus serum diluted 1:2,000 in PBS buffer at 37°C for 2 hours and followed by
incubation with a second antibody mouse anti-rabbit IgG conjugated with alkaline
phosphate at a 1:80,000 dilution in PBS buffer at 37°C for 2 hours. The plate was finally
incubated with chemiluminescent substrate, Lumi-phos Plus (Luminogen, Inc.) for 30
minutes at 37°C, and the plate was read in Microtiter Plate Luminometer (Dynatech). The
light emissions were recorded as relative light units (RLU) over the background.

d. Mouse Oral Immunization
In our immunization regimen, transgenic potato tuber slices were fed a total of four
times on days 0, 7, 17, and 24 of the experiment, to a group of 10 female CD-I mice. On
each antigen inoculation day, lOug of purified bacterial cholera toxin (Sigma) was first
administered as an adjuvant to the mice in 0.4 ml sodium bicarbonate buffer (350 mM),
pH 8.5 by gastric intubation (gavage). The mice were then fed 5 g of transgenic tuber
slices containing approximately 15 pg of VP6 protein as previously determined by
ELISA and immunoblot assays. Following the same feeding protocol, a group of 5 CD-I
mice were each fed 5 g of untransformed potato tuber slices to serve as a negative
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control. Another group of 10 mice was fed the same amount of purified bovine rotavirus
VP6 protein (15 pg) mixed with 10 pg cholera toxin by gavage as a positive control. On
day 23 after the fourth feeding the mice were sacrificed. Blood was collected from each
CO2 anaesthetized mouse by heart puncture. The small intestines of the sacrificed mice
were removed and the lumen of the intestine was washed with 1 ml PBS buffer, pH 8.5,
containing lOmM PMSF to collect any mucosal antibodies. Both blood and intestinal
samples were tested for serum IgG and mucosal IgG and IgA titers by chemiluminescent
ELISA methods.

3. Results
a. Plant Expression Vector and Transformation of Potato Plants
Plant expression vector pPCVTOl VP6 contains a 430 bp DNA fragment encoding the
mannopine synthase dual promoters (mas PI, P2). The mas P2 promoter controls the
expression of the rotavirus VP6 gene. In addition, the plant expression vector contains the
p-lactamase gene for ampicillin resistance in E.coli and carbenicillin resistance in A.
tumefaciens. The neomycin phosphotransferase II gene (NPTII) cassette provides
kanamycin selection in transformed plants (Figure 1). The T-DNA sequence containing
the VP6 gene located between the left and right borders (RB and LB) became randomly
integrated into the plant genome during A.tumefaciens mediated stable transformation
used in our laboratory. A total of five transformed VP6 producing plants were
regenerated.
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b. Immunoblot Detection of VP6
Tuber and leaf tissues from the transformed plants were analyzed for the presence of
VP6 protein by immunoblot assay. Transformed plant produced VP6 protein was
identified by rabbit anti-rotavirus serum (Figure 2, lane 4) and thus retained the
antigenicity of the native viral VP6 protein. The molecular size of the plant synthesized
VP6 protein was 45 kD, which is the approximate size of the native bovine virus VP6
(Figure 2, lane 2). Like the bovine virus VP6, plant produced VP6 underwent partial
assembly into 120 kD VP6 trimers detected by unreduced SDS/PAGE gel
electrophoresis. The formation of VP6 multimers may be essential for retaining immuno
dominant conformational epitopes that stimulate protective immune response.
Untransformed tuber tissue samples (Figure 2, lane 3) did not react with the anti-rotavirus
antiserum.

c. Quantification of VP6 in Transformed Plants
The VP6 protein expression levels in transformed potato leaf and tuber tissues were
measured by quantitative chemiluminescent ELISA. Two standard curves (0.1% and
0.01%) VP6 protein were generated based on chemiluminescent signals provided by the
anti-VP6 antibody complex (Figure 3). The relative light units (RLU) values obtained by
measurement of serial dilutions of transgenic plant homogenates were plotted against the
amount of total soluble protein in the transformed tuber extracts. The transgenic tuber
tissues were found to produce approximately 0.01% VP6 of total soluble protein (Figure
3). The ability of plant synthesized VP6 to bind two different anti-VP6 sera in a sandwich
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ELISA confirmed the native structure and biological activity of the plant synthesized
VP6 protein.

d. Immunogenicity of the Plant Produced Rotavirus VP6 Protein
CD-I mice were fed transgenic potato tubers to test the oral immunogenicity of plant
derived VP6. When tuber slices containing 15 pg VP6 protein were fed concomitantly
with 10 pg CT, 10 out of 10 mice developed detectable serum IgG levels against VP6
with anti-VP6 titers ranging from 1:80 to 1:1280. When the same amount of purified
virus VP6 protein was fed along with 10 pg CT as adjuvant, 10 out of 10 mice responded
by producing serum anti-VP6 IgG titers ranging from 1:500 to 1:16,000. The titers of
antibodies raised against pure VP6 protein were higher than titers raised against plant
derived VP6. In addition to significant serum IgG titers, plant expressed VP6 also
stimulated a detectable intestinal anti-VP6 IgA response in 7 out of 10 mice. Rotavirus
VP6 protein stimulated the production of intestinal IgA in 6 out of 10 immunized mice.
The percentage of mice responding to VP6 challenge and the intestinal IgA titers
obtained following immunization with plant produced VP6 was comparable to the results
found from oral immunization with pure virus VP6 protein (Table 1). Both IgG and IgA
antibodies generated against VP6 protein were detected in serum and intestinal samples
taken from CD-I mice immunized with plant produced VP6 (Figure 4). Serum IgG
demonstrated the highest titers, which indicated successful stimulation of the systemic
immune system. The presence of measurable mucosal antibody titers indicated a
successful immune response at the local site. Most IgA antibody presents at the mucosal
surface in a form of secretory IgA, the function of the small amount of serum IgA is
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unknown. It probably exists in a form of precursor IgA before it is transferred to the
mucosal surface by the transcytosis mechanism. Mice fed untransformed tuber tissues did
not develop any specific anti-VP6 antibodies.

4. Discussion
Plants can produce viral and bacterial antigens that retain their biological activities
and functions essential for plant based oral vaccine development (Mason et ah, 1992,
1996; Haq et al., 1995; Modelska et ah, 1998). Expression of individual rotavirus
antigens in plants allows us to determine which rotavirus proteins may be most active in
protection against virus infection and to determine the role of non-neutralizing antibodies
in disease prevention (Ishida et al, 1997; Ball et al., 1996). The rotavirus capsid protein
VP6 is a virus structural protein that is highly immunogenic. Specific antibodies against
VP6 can be detected in the sera of clinical patients (Bums et al, 1995; Eydelloth et al.,
1984). The role of VP6 antibody in protection against disease onset has already been
demonstrated in several different aspects. A VP6 DNA vaccine was shown to protect
mice from rotavims challenge. Hybridoma cells secreting anti-VP6 IgA in a “back pack”
mouse model provided protection from rotavims infection by an IgA transcytosis
mechanism (John et al, 1996). Dr.Estes and her colleagues also showed that VP2/VP6
VLPs achieved the same level of protective efficacy as obtained by immunization with
2/6/7 VLPs without requirement for the neutralization antigens VP7 and VP4 (Conner et
al., 1996). In the present study, we have demonstrated that VP6 protein produced in
transgenic potatoes retained its antigenicity and partially folded into multimers, which
may be important for the formation of conformational epitopes to provide increased

126

immunogenicity. Oral immunization in mice stimulated both humaral and mucosal
antibody production, indicated a successful delivery of the VP6 antigens to the mucosal
immune system. The presence of intestinal IgA, which is strongly correlated with
protection in vivo indicated a protective immune response was generated by the plant
produced VP6 (Hoshino and Kapikian, 1994).
The A. tumefaciens mannopine synthase promoter is a dual promoter providing the
advantage of coordinate expression of two foreign genes simultaneously in transformed
plant tissues (Langridge et al., 1989). Since the P2 promoter is 2-10 times more active
than PI promoter, we selected the mas P2 promoter to drive the expression of the VP6
gene. In plant homogenates of transformed tuber tissues we were unable to detect VP6
VLPs by transmission electron microscopy. However rod-like structures were detected
present in transformed tissue homogenates only which may be due to the aggregation of
VP6 proteins (data not shown) (Ready and Sabara, 1987). The availability of the mas PI
promoter in our plant expression vector allows us to clone additional rotavirus capsid
genes into potato such as the VP2 gene. This will provide us with the opportunity to
generate VP2/VP6 VLPs in transgenic plants to provide greater protective efficacy to the
present plant-based vaccines. The production of the mammalian rotavirus VP6 protein
monomers and aggretates in potato plants and demonstration of oral immunogenicity in
CD-I mice is the first successful step toward the development of a protective rotavirus
subunit vaccine in plants.
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Figure 1. Plant expression vector pPCV701VP6. Figure 1. Shows the transferred DNA (T-DNA) sequence of the plant
expression vector pPCV701 VP6 used for transformation of potato plants. RB and LB are the right and left borders required for
integration of the T-DNA into the plant genomic DNA. The C-DNA of rotavirus VP6 was cloned into P2 side of the mannopine
synthase {mas) dual promoter. A (3-lactamase gene cassette (Bla) was included in the T-DNA to provide resistance against
ampicillin for selection in E.coli and carbenicillin for selection in A.tumefaciens. The NPTII gene expression cassette was
included to provide resistance to kanamycin for selection of transformed plants.
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Figure 2. Immunoblot detection of VP6 protein in transgenic potato tuber tissues.
The VP6 protein was detected with anti-VP6 antibody as the primary antibody and
alkaline phosphatase conjugated anti-rabbit IgG as the second antibody. Lane 1,
molecular weight markers; Lane 2, 100 ng purified bovine rotavirus VP6 protein; Lane 3,
100 pg total soluble protein (TSP) from an untransformed potato plant; Lane 4, 100 pg
TSP from potato plants transformed with VP6 gene.
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Figure 3. Determination of VP6 protein levels in transformed potato plants. The VP6 protein levels in transformed potato
tissues were measured by chemiluminescent ELISA. Known amounts of purified rotavirus VP6 protein were mixed with plant
homogenates from untransformed potato tissue to generate two standard curves (0.1% and 0.01% VP6 protein). Homogenates
from untransformed plants were used as negative controls. The relative light units (RLU) obtained from the samples were
measured in comparison with the standard curves to calculate VP6 protein expression levels.
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Figure 4. Measurement of anti-VP6 antibody titers in mice after oral immunization with transgenic potato tuber tissues.
CD-I mice were fed transgenic potato tubers containing 15 pg of VP6 protein with 10 pg of cholera toxin as adjuvant. Mice fed
untransformed potato tubers served as a negative control. Serum and intestinal IgG and IgA titers against VP6 protein were
determined by a chemiluminescent ELISA as described in the methods section. The antibody titer was defined as the reciprocal
of the highest dilution of the serum sample or intestinal contents that generated a luminescence signal above background levels.
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Table 1. Immune response of CD1 mice fed VP6 protein

Group

VP6
VP6
protein protein
origin
(ug)

Delivery

Serum IgG

Adjuvant

Intestinal IgA

No. positive / Titer, range No. positive/
total
total

Titer, range

1

15

virus

gavage

lOug CT

10/10

500-16,000

6/10

8-32

2

15

tuber

feed

lOug CT

10/10

80-1280

7/10

16-128

3

0

tuber

feed

none

0/5

0/5

<4

o

<4

Serum and intestinal anti-VP6 IgG and IgA titers were measured by chemiluminescent ELISA methods. The antibody
was defined as the reciprocal of the highest dilution of the serum or intestinal sample that generated luminescence
Signal above background levels.

CHAPTER SEVEN
CONCLUSIONS AND FUTURE PERSPECTIVES
1. Plants as Vaccine Production and Delivery Systems
Plants are traditional sources of food, fiber and medicinal compounds. Recent
developments in plant biotechnology have facilitated the production of a variety of
economically or pharmaceutically important recombinant proteins in transgenic plants
(Hein et ah, 1996, Hiatt et ah, 1989, McGarvey et ah, 1995). An increasing number of
investigators have demonstrated plant production of antigenic proteins from viral and
bacterial pathogens and that these proteins elicit immune responses and even protection
against pathogen challenge, by oral and/or parenteral administration (Dalsgard et ah,
1997, Haq et ah,1995; Modelska et ah, 1998). Plant-based vaccine production and
delivery systems have attracted the interest of governmental agencies, Agri-business and
pharmaceutical companies for commercialization of vaccines (Ma and Vine, 1999;
Mason et ah, 1995). However, prior to commercialization the potential of plant vaccines
to generate protection against individual diseases must be developed in animal model
systems (preclinical trials) followed by toxicity and efficacy testing in human phase I and
II clinical trials (Moffat, 1995; Mor et ah, 1998).
a. Multicomponent Vaccines
From a clinical perspective, it would be very useful to express antigens of multiple
pathogens in one plant. Protection against several infectious diseases could be achieved
by oral administration of a multi-component food plant-based vaccine. Stimulated by the
World Health Organizaiton’s request for a simple vaccine for protection against severe
enteric pathogens we have produced multiple antigen proteins (CTB, NSP4, CFA/I) for
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protection against severe enteric diseases (cholera, ETEC, rotavirus) in a single potato
plant. The disease antigen proteins synthesized in the plant have retained their
antigenicity. Oral inoculation of mice with potato tuber tissues containing the three
antigens stimulated both humoral and mucosal immune responses against the three
antigens, which provided protection against both viral and bacterial pathogen challenge.
Thus, we were able to demonstrate for the first time the protective efficacy of a multicomponent food plant based vaccine.
The CTB subunit expressed in the transformed potato tubers not only functioned as a
vaccine for protection against the diarrhea caused by cholera toxin, but in addition the
CTB subunit was found to function well as a carrier molecule for specific targeting to
enterocyte cells of the mucosal epithelium and as an immune modulation molecule
(adjuvant) for sensitizing and stimulating the mucosal immune system. The novel
approach of targeting the disease antigen to the GALT via CTB-antigen fusion protein
has greatly reduced the amount of the antigen required for the development of significant
mucosal immune response. The recent discovery that the CTA2 subunit can be inserted
into the CTB pentamer in plant cells forms the foundation of the carrier system capable
of targeting additional antigens to the mucosal immune system. In the dissatation we have
demonstrated that five copies of a small peptide such as NSP4 containing approximately
20 amino acid residues can be genetically fused to the CTB pentamer; while one copy of
large peptide up to 50 kD such as CFA/I can be linked to the CTA2 subunit and inserted
stably into the CTB pentamer without disrupting the pentamer structure. The resultant
double fusion protein structurally and functionally resembles the cholera holotoxin with
the further attribute of delivery additional antigen to the GALT. The design of the CTA2-
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CTB hetero-hexameric enterocyte targeted carrier system has opened the way for the
expression of a variety of antigen combinations from diverse origins for control of
infectious diseases.
b. Multivalent Vaccine
Vaccines composed of single antigen are able to confer a limited degree of immunity
against a single pathogen. A more ideal vaccine will be one that is able to induce
antibody protection against bacterial or viral pathogen structural proteins in addition to
the enterotoxins they secrete. Based on this concept we have designed a multivalent
plant-based vaccine against rotavirus disease utilizing the CTA2-CTB carrier system. A
DNA fragment encoding the rotavirus capsid proteinVP6 gene was genetically linked
with CTA2 sequence and a nucleotide sequence encoding the CTB gene linked to the
rotavirus entertoxin NSP4 epitope (114-135). A plant expression vector containing the
two rotavirus fusion genes was transferred into A. tumefaciens. Transformed potato
plants were generated by A. tumefaciens mediated stable transformation methods used in
our laboratory. Identification of the plant synthesized rotavirus antigens is currently in
progress. By taking advantage of the CTA2-CTB system, we expect to develop a plantbased multivalent vaccine against rotavirus with enhanced protective efficacy against
rotavirus challenge.
c. Plant-based VLPs Vaccines
In 1996, Mason and his colleagues reported the expression of Norwalk virus capsid
protein in transformed tobacco and potato tissues (Mason et ah, 1996). These capsid
proteins formed single layered, empty virus like particles (VLPs), which were
morphologically and immunogenically identical to mature virus particles. Containing
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four capsid proteins, rotavirus is structurally more complex than Norwalk virus. In our
attempt to create a plant VLPs vaccine against rotavirus, we first expressed the most
abundant rotavirus capsid protein VP6 in transgenic potatoes. Plant-produced VP6
proteins with a molecular mass similar to their virus VP6 counterpart. In addition, plant
synthesized VP6 was able to react with anti-VP6 antiserum and VP6 protein partially
assembled into trimers, which indicated the presence of molecular structure responsible
for the capsid protein folding. Rod shaped structures were detected by transmission
electron-microscopy in extracts of transgenic potato tissues, which were not detected in
untransformed potato samples (data not shown). Previous transmission electron
microscopic studies of purified bovine rotavirus VP6 protein demonstrated the presence
of tubular particles which were formed between pH 5.0 and 9.0. Spherical particles
resembling single-shelled virus were formed at pH 4.0, while sheet-like structures formed
between pH6.0 to pH 4.0 (Ready and Sahara, 1987). Thus, the rod shaped structures that
we observed in Tris-HCl buffer extracts of transformed potato leaves (pH 8.0) may be
due to partial assembly of the VP6 capsid protein. In the future we will purify the plant
synthesized VP6 proteins from plant homogenates by glucose gradient centrifugation and
try to identify the VP6 protein assembly into single shelled virus like particles at
appropriate pH conditions.
The mas dual promoter in the plant expression vector (pPCV701) is bi-directional,
and can drive expression of two genes simultaneously in opposite directions (Langridge
et al, 1989). Taking advantage of this unique characteristic, we cloned the rotavirus VP2
gene down stream of the mas P2 promoter and the VP6 gene downstream of the mas PI
promoter. Transformed potato plants expressing both VP2 and VP6 capsid proteins were
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regenerated. Co-expression of VP2 and VP6 proteins was detected on immunoblots,
Detection of double layered VP2/6 VLPs in plant tissues by transmission electron
microscopy remains to be attempted.
2.

The Role of Cholera Toxin in Immune Modulation

a.

Adjuvanticity of CT and the CTB Subunit
Cholera toxin is one of the most potent mucosal immunogens yet identified. The

holotoxin induces strong intestinal S-IgA and serum IgG responses following oral
adminsitration (Elson and Balding, 1984, Fujita et ah, 1972). Despite its remarkable
properties as a mucosal immunogen, the mucosal immune response to CT follows rules
applicable to most conventional protein antigens in that the immune response is CD4+ T
cell dependent and requires antigen presentation via class II MHC molecules (Jackson et
ah, 1993). The adjuvanticity of CT appears to be linked to its immunogenicity (Freytag
and Clement, 1999). The effectiveness of the plant-produced CTB subunit as a mucosal
adjuvant was clearly demonstrated by the immune response detected following oral
immunization with the plant synthesized CTB-NSP4 fusion protein. When the NSP4
peptide was genetically conjugated to CTB it elicited higher antibody levels in serum
than feeding either NSP4 alone or an unconjugated mixture of NSP4 and CTB proteins.
Protein fusions based on the GM1 ganglioside binding activity of CTB subunit greatly
reduced the amount of antigen protein required to stimulate a mucosal immune response
(Holmgren et ah, 1996). Oral administration of plant-produced CFA/I-CTA2 and CTBNSP4 fusion proteins as low as 7 pg/ dose was able to generate measurable titers of both
serum and intestinal antibodies. The long term T cell response induced by the plantderived cholera toxin fusion protein was demonstrated by flow cytometry assay.
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Increased CD4+ memory T cell populations were detected in spleen cells from orally
immunized mice as early as 14 days after vaccination and persisted for two months
following immunization.
The mechanism of CTB enhancement of the mucosal immune response has not been
clearly determined. Previous experiments have demonstrated that many cellular events
are triggered by the CTB-Gmi ganglioside receptor interaction (Lycke and Holmgren,
1986). Intestinal epithelial cells are recognized as active antigen presenting cells of the
mucosal immune system. They express both class I and class II MHC molecules, produce
certain cytokines and respond to an even larger array of cytokines. Cholera toxin
stimulates the production of IL-6 by the epithelial cell in vitro. Cholera toxin also
stimulates the production of IL-1 and IL-6 by macrophages, which provide costimulatory
signals to T helper cells. Increased T cell priming was observed in mucosal tissues in vivo
when CT was used as an adjuvant.
b. The Thl vs Th2 Lymphocyte Response
Murine CD4+ helper T cells have been subdivided into Thl and Th2 subtypes based
on the pattern of cytokines which they secrete (Mosmann and Coffman, 1989). The Thltype helper cells secrete 11-2 and IFNy whereas Th2-type helper cells produce IL-4, IL-5,
IL-6, IL-10 and IL-13 (Kjerrulf et al, 1998). Several of the Th2 cytokines have been
shown to be important in generating IgA responses and this Th2 subtype may be
preferentially expressed in mucosal follicles such as Peyer’s patches (Lehman et al.,
1988; Lycke et al., 1983). In mice the IgG2a isotype antibody response is Thl dependent,
whereas IgGl isotype and IgE antibody responses are Th2 dependent.
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The mechanisms by which a given antigen triggers a Thl or Th2 lymphocyte
dominated response are at present unclear. The CTB subunit tends to stimulate a Th2
immune response (Marinaro et al., 1999; Xu-Amano et al., 1994). Binding of the CTB
pentamer to intestinal epithelium cell surface ganglioside receptors results in induction of
CD25 on macrophage and lymphocyte populations. Such activation is associated with
subsequent apoptotic dell death of CD8+ T cells, enhanced expression of MHC class II
on B cells and CD40L on CD4+ T cells (Homquist and Lycke, 1993). Macrophage
activation is associated with release of IL-10. The Thl cytokine release is down-regulated
as a result of decreased IFNy production, through loss of CD8+ T cells and IL-10
mediated suppression of Thl activation by antigen-presenting cells (Romagnani, 1994).
Concomitantly, enhanced T cell-B cell interactions leading to up-regulation of B7, CD40,
and ICAM-1 on B cells and CD40L on CD4+ cells increases the commitment towards
Th2 cytokine production.
Based on cytokine analysis we detected a Thl type immune response in mice orally
immunized with plant-derived CFA/I-CTA2 and CTB-NSP4 fusion proteins. Previous
reports showed that CTB fusion proteins favor a Th2 type immune response (Marinaro et
al., 1999; Xu-Amano et al., 1994). The disparity between our experimental results and
previously reported studies may be explained by the following reasons. Antigens coupled
to the CTB subunit may influence the type of immune response being induced. A Th2
cell response is induced by CTB fusion with either self antigens such as insulin, glutamic
acid decarboxylase (GAD), myelin basic protein (MBP) or with nonpathogenic antigens
such as ovalbumin (OVA), bovine gamma globulin (BGG) (Khoury et al, 1990; Melamed
and Friedman, 1993; Miller et al., 1991). Bacterial or viral antigens such as inactivated
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repiratory syncytical virus and tetanus toxoid fragment C plus CT as an adjuvant induce a
Thl cell response. When purified CFA/I or NSP4 antigen proteins were added to spleen
cell cultures, we detected increased expression levels of IL-2 and IFNy, which indicated
the presence of a Thl cell response. Thus, it was not unexpected to see a Thl immune
response in mice fed trangenic potato tissues containing the CTA2-CFA/I and CTBNSP4 double fusion proteins.
c. Immune Response vs Immune Tolerance
When CT is used as a mucosal adjuvant, it has the potential to stimulate the synthesis
of a broad range of cytokines such as II-1,11-2, IL-4, IL5, IL6, IL10, and IFNy
accompanied by an enhanced proliferative response of both Thl and Th2 type CD4+ T
precursor cells. When an antigen (autoantigen) which stimulates a Th2 cell response is
conjugated with CTB, it selectively activates suppressor T-cells (Arakawa et al., 1998;
Sun et al., 1994; Trentham et al., 1993). The suppressor T cells migrate from the GALT
into the systemic circulation. When the suppressor T cells encounter the autoantigen at
the target organ, they secrete suppressor cytokines such as IL-4, IL-10 and transforming
growth factor (TGF)-(3 which results in a down-regulation of the autoreactive T-cells
(Czerkinsky et al., 1995; Trentham et al., 1993). When a Thl cell-inducing antigen (viral
or intracellular bacterial antigens) is encountered, IL-2, IFNy levels are up-regulated
accompanied by the activation of cytotoxic T lymphocytes. Prolonged CTantigen/autoantigen feeding studies will be necessary to provide a more complete
understanding of the immune modulation effects of CT which will help us to further our
understanding of the mechanisms involved in the regulation of mucosal immunity.
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3. Plant Vaccines’ Future Perspectives
Plants are one of the most inexpensive sources of protein and therefore, potentially
also one of the cheapest sources of recombinant proteins, even if purification of the
protein is required. The potential for production scale-up can make plant vaccines the
most cost effective vaccines yet developed (Amtzen, 1997, 1998). However some basic
questions must be addressed. One of the biggest obstacles to an effective plant-based
vaccine remains the low level of accumulation of foreign antigens in plant tissues. This
problem becomes even more acute for less immunogenic antigens. Manipulation of
antigen encoding genes at both the transcriptional and translational levels may increase
the expression levels of recombinant protein in the plant. Such strategies include addition
of transcriptional and translational enhancer sequence, addition of leader peptides,
addition of ER retention signals (Schouten et al., 1996), application of constitutively
expressed promoters, adjustment of the codon usage to favor plant gene expression, and
removal of RNA splice sequences and intron sequences (Ma et al, 1999; Tsafrir et al.,
1998). However there may be limitations to how much foreign proteins can synthesized
or accumulated in plant cells. Alternative solutions to increased production of antigen
proteins in plants include improved targeting of antigen molecules to the mucosal
immune system, which could considerably reduce the amount of plant-produced antigen
protein required for successful oral immunization (Arakawa et al., 1998). An
accumulating body of evidence indicates that the cholera toxin B subunit is an effective
carrier molecule for targeting antigens specifically to receptors on the intestinal epithelial
cell membrane. The HIV transactivation sequence (TAT) is another non-specific
targeting protein under active investigation in our laboratory (Barka et al., 2000).
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Mutated cholera toxin A subunit that has no toxicity, yet maintains strong adjuvant
activity, can also be employed to increase the mucosal immune response. Another
possible solution to accumulate plant-produced antigen protein might be the addition of a
plant secretion signal to the antigen protein. Recombinant proteins produced by the plant
will be continuously secreted into the liquid culture media, never reaching a toxic level
that might compromise the fitness of the transgenic plant. Simple purification steps may
harvest large amounts of recombinant proteins accumulated in liquid culture media.
Under sterile environmental conditions of optimal temperature and light, trangenic plants
can produce foreign proteins approaching 24 hours a day. The expression levels of
antigen protein in the plant may influence the dose of plant vaccine delivered for
immunization. This source of antigen variability might be reduced by minimal processing
of the plant material, for example, freeze drying followed by grinding and mixing the
dried tissues to create uniform batches of plant-based antigen. Foreign proteins are
frequently subjected to post-translational modifications in the plant cells following
synthesis (McGarvey et al., 1995). Post-translational processes such as correct protein
folding, glycosylation and proteolysis may greatly affect antigen stability and
immunogenicity. While post-translational modification in plants is similar to that found
in animal cells, small but critical changes may occur. Therefore, efforts to study the
structure and function of plant-produced antigen proteins must be emphasized. Further,
the issue of biological safety must also be addressed. Regulations for the use of trangenic
plant tissues for vaccine purposes must be established before human clinical trials are
initiated. Finally the environmental impact of growing transgenic plants in the field must
be assessed to settle issues of public safety. Thus, considerable research and education of
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the public concerning appropriate applications of plant-based vaccines still needs to be
accomplished before children can be simply vaccinated with a glass of tomato juice or a
slice of transgenic banana.
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